<SEC-DOCUMENT>0001213900-26-065389.txt : 20260604
<SEC-HEADER>0001213900-26-065389.hdr.sgml : 20260604
<ACCEPTANCE-DATETIME>20260604172559
ACCESSION NUMBER:		0001213900-26-065389
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20260604
DATE AS OF CHANGE:		20260604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iSpecimen Inc.
		CENTRAL INDEX KEY:			0001558569
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				270480143
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-296512
		FILM NUMBER:		261066084

	BUSINESS ADDRESS:	
		STREET 1:		8 CABOT ROAD
		STREET 2:		SUITE 1800
		CITY:			WOBURN
		STATE:			MA
		ZIP:			08101
		BUSINESS PHONE:		781-301-6700

	MAIL ADDRESS:	
		STREET 1:		8 CABOT ROAD
		STREET 2:		SUITE 1800
		CITY:			WOBURN
		STATE:			MA
		ZIP:			08101
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ea0291637-s3_ispecimen.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>As
filed with the Securities and Exchange Commission on June 4, 2026</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
No. <FONT STYLE="background-color: white">333-</FONT></B></FONT><B><FONT STYLE="background-color: white">[*]</FONT></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>UNDER</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>THE SECURITIES ACT
OF 1933</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>iSpecimen Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>8731</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>27-0480143</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or
                                    jurisdiction of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard
                                    Industrial</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>8 Cabot Road, Suite 1800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Woburn, MA 01801</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (781) 301-6700</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address, including zip
code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Katharyn Field</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>8 Cabot Road, Suite 1800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Woburn, MA 01801</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(781) 301-6700</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ross D. Carmel, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Barry P. Biggar, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Benjamin E. Sklar, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sichenzia Ross Ference Carmel LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1185 Avenue of the Americas</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10036</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phone: (212) 930-9700</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate date of commencement of proposed
sale to the public:</B> As soon as practicable after the effective date of this registration statement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
box. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If delivery of the Prospectus is expected to
be made pursuant to Rule 434, check the following box. &#9744;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt; width: 20%"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.5pt; padding-bottom: 0.5pt; width: 17%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt; width: 24%"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt"><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.5pt; padding-bottom: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt"><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 0.5pt; padding-bottom: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt"><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission acting pursuant
to said Section 8(a) may determine.</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B>The information in this preliminary
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer
to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
    PROSPECTUS SUBJECT TO COMPLETION</B></FONT></TD>
    <TD STYLE="width: 40%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATED JUNE 4, 2026</B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ea029163701_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>488,290 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the offer and resale of up to an aggregate
of 488,290 shares of common stock, par value $0.0001 per share (&ldquo;Common Stock&rdquo; or &ldquo;common stock&rdquo;), of iSpecimen
Inc., held by selling stockholders, consisting of the following: (i) up to 85,202 shares of common stock (the &ldquo;Shares&rdquo;) issued
in connection with the May 2026 Private Placement (as defined below), and (ii) up to 403,088 shares of common stock (the &ldquo;Warrant
Shares&rdquo;) issuable upon exercise of pre-funded warrants (the &ldquo;Pre-Funded Warrants&rdquo;) issued in connection with the May
2026 Private Placement, all of which were issued by us in connection with a private placement transaction completed on May 11, 2026 (the
&ldquo;May 2026 Private Placement&rdquo;) pursuant to a securities purchase agreement, dated as of May 8, 2026 (the &ldquo;Purchase Agreement&rdquo;).
The selling stockholders acquired the securities covered by this prospectus pursuant to the Purchase Agreement. The holders of the Shares
and Warrant Shares are each referred to herein as a &ldquo;Selling Stockholder&rdquo; and collectively as the &ldquo;Selling Stockholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus also covers any additional shares
of common stock that may become issuable by reason of stock splits, stock dividends, and other events described in the Pre-Funded Warrants
or the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders, or their respective
transferees, pledgees, donees or other successors-in-interest, may sell the Shares and Warrant Shares through public or private transactions
at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The Selling Stockholders
may sell any, all or none of the securities offered by this prospectus, and we do not know when or in what amount the Selling Stockholders
may sell their shares hereunder following the effective date of this registration statement. We provide more information about how a Selling
Stockholder may sell its shares in the section titled &ldquo;Plan of Distribution&rdquo; on page 14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering the Shares and Warrant Shares
on behalf of the Selling Stockholders, to be offered and sold by them from time to time. We will not receive any proceeds from the sale
of our common stock by the Selling Stockholders in the offering described in this prospectus. We may, however, receive nominal proceeds
from any cash exercise of the Pre-Funded Warrants. Assuming the cash exercise in full of all outstanding Pre-Funded Warrants at the exercise
price of $0.0001 per share, we would receive aggregate gross proceeds of approximately $40.00. The Pre-Funded Warrants are exercisable
on a cashless basis, and we expect that the Selling Stockholders will exercise the Pre-Funded Warrants on a cashless basis, in which case
we would not receive any proceeds from such exercise. Any proceeds we receive from the cash exercise of the Pre-Funded Warrants will be
used for working capital and general corporate purposes. The Selling Stockholders will pay any agents&rsquo; commissions and expenses they incur
for brokerage, accounting, tax or legal services or any other expenses that they incur in disposing of the shares of common stock. We
have agreed to bear all of the expenses incurred in connection with the registration of the Shares and Warrant Shares. The Selling Stockholders
will pay or assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred
for the sale of the Shares and Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is currently listed on the Nasdaq
Capital Market under the symbol &ldquo;ISPC.&rdquo; On May 29, 2026, the last reported sale price for our common stock was $3.16 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
as the term is used in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;) and, as such, have elected to comply
with certain reduced public company reporting requirements for this and future filings. This prospectus describes the general manner in
which the Shares and Warrant Shares may be offered and sold. If necessary, the specific manner in which the Shares and Warrant Shares
may be offered and sold will be described in a supplement to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our Common Stock involves risks.
You should carefully review the risks described under the heading &ldquo;Risk Factors&rdquo; beginning on page 10 before you invest in
our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is [*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 9%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001">About this Prospectus</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">ii</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_002">Special Note Regarding Forward Looking Statements</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">iii</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003">Prospectus Summary</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_004">Risk Factors</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005">Use of Proceeds</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_014">May 2026 Private Placement</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_015">Selling Stockholders</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_016">Plan of Distribution</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_017">Legal Matters</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_018">Experts</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_001">Incorporation of Certain Information by Reference</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_019">Where You Can Find More Information</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">15</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus describes the general manner in which the Selling Stockholders
may offer from time to time the Shares and Warrant Shares. You should rely only on the information contained in this prospectus or incorporated
by reference into this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated
by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Stockholders have authorized
anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely
on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation of an offer
to purchase, the common stock offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction to or from
any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should not assume
that the information contained in this prospectus, any prospectus supplement or amendments thereto, as well as information we have previously
filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), is accurate as of any date other than the date on the
front cover of the applicable document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If necessary, the specific manner in which the Shares and Warrant Shares
may be offered and sold will be described in a supplement to this prospectus, which supplement may also add, update or change any of the
information contained in this prospectus. To the extent there is a conflict between the information contained in this prospectus and any
prospectus supplement, you should rely on the information in such prospectus supplement, provided that if any statement in one of these
documents is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference
in this prospectus or any prospectus supplement - the statement in the document having the later date modifies or supersedes the earlier
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the delivery of this prospectus nor any distribution of Shares
or Warrant Shares pursuant to this prospectus shall, under any circumstances, create any implication that there has been no change in
the information set forth or incorporated by reference into this prospectus or in our affairs since the date of this prospectus. Our business,
financial condition, results of operations and prospects may have changed since such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When used herein, unless the context requires
otherwise, references to the &ldquo;iSpecimen,&rdquo; &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo;
refer to iSpecimen, Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Trademarks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus contains references to trademarks
and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may
appear without the &reg; or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will
not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display
of other companies&rsquo; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us
by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the documents incorporated
by reference herein contain various forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E
of the Securities and Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) that reflect our current expectations and views
of future events. Readers are cautioned that known and unknown risks, uncertainties and other factors, including those over which we
may have no control and others listed in the &ldquo;Risk Factors&rdquo; section of this prospectus and the documents incorporated by
reference herein, may cause our actual results, performance or achievements to be materially different from those expressed or implied
by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You can identify some of these forward-looking
statements by words or phrases such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;aim,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;is/are likely to,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue&rdquo; or other similar expressions. We have based these forward-looking statements largely on our current expectations
and projections about future events that we believe may affect our financial condition, results of operations, business strategy and
financial needs. These forward-looking statements include statements relating to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to enter into contracts with healthcare
    providers to gain access to specimens, subjects, and data on favorable terms;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to obtain new customers and keep existing
    customers;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">development of our technology to adequately keep pace
    to support expansion of our existing line of business or our entry into new lines of businesses;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">market adoption rate of our marketplace technology;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to continue to expand outside of the United
    States in compliance with local laws and regulations;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">our business model generally;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">acceptance of the products and services that we market;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">the viability of our current intellectual property;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">government regulations and our ability to comply with
    government regulations;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to retain key employees;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">adverse changes in general market conditions for biospecimens;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to generate cash flow and profitability
    and continue as a going concern;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">our future financing plans; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; width: 0.25in; padding: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; white-space: nowrap; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to adapt to changes in market conditions
    which could impair our operations and financial performance.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements involve numerous
risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our
expectations may later be found to be incorrect. Our actual results of operations or the results of other matters that we anticipate
could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially
different from our expectations are generally set forth in &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; &ldquo;Business,&rdquo; &ldquo;Regulation&rdquo; and other sections included
or incorporated by reference in this prospectus. You should thoroughly read this prospectus and the documents incorporated herein by
reference with the understanding that our actual future results may be materially different from and worse than what we expect. We qualify
all of our forward-looking statements by these cautionary statements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The forward-looking statements made in this prospectus
relate only to events or information as of the date on which the statements are made in or incorporated by reference in this prospectus.
Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result
of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated
events. You should read this prospectus, the documents incorporated by reference into this prospectus and the documents we have filed
as exhibits to the registration statement, of which this prospectus forms a part, completely and with the understanding that our actual
future results may be materially different from what we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>PROSPECTUS SUMMARY</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights, and is qualified
in its entirety by, the more detailed information and financial statements included elsewhere in this prospectus. This summary does not
contain all of the information that may be important to you in making your investment decision. You should read this entire prospectus
carefully before making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Unless otherwise noted, the share and per share information in this
prospectus reflects (i) a reverse stock split of the outstanding common stock of the Company at a ratio of 1-for-20, which was effected
on September 13, 2024, and (ii) a reverse stock split of the outstanding common stock of the Company at a ratio of 1-for-40, which was
effected on April 27, 2026 (with the Company&rsquo;s common stock beginning trading on a split-adjusted basis on April 28, 2026).</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Mission, Vision, and Core Values</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">iSpecimen&rsquo;s mission is to accelerate life
science research, discovery and development with a global marketplace platform that connects researchers to subjects, specimens, and
associated data. Our vision is to create an &ldquo;Amazon-like&rdquo; global Marketplace of patients, biospecimens, and data for research
to improve the quality of human life. We implement employee programs that foster a company culture predicated on the core values of corporate
and individual growth, results and accountability, team before self; a can-do positive attitude, and the perseverance to succeed.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">iSpecimen is a technology-driven company founded
to address a critical challenge: how to connect life science researchers who need human biofluids, tissues, and living cells (&ldquo;biospecimens&rdquo;)
for their research, with the billions of biospecimens available (but not easily accessible) in healthcare provider organizations worldwide.
Our ground-breaking iSpecimen Marketplace platform was designed to solve this problem and transform the biospecimen procurement process
to accelerate medical discovery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The iSpecimen Marketplace brings new capabilities
to a highly fragmented and inefficient biospecimen procurement market. Our technology consolidates the biospecimen buying experience
in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia,
and government institutions who need them. We are seeking to transform the world of biospecimen procurement much like the way travel
websites changed the consumer buying process for flights, hotels, and rental cars.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The iSpecimen Marketplace Solution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The iSpecimen Marketplace offers single-source
access to millions of human biospecimens and patients across a diverse network of specimen providers quickly and compliantly, saving
researchers time and money in their specimen procurement process while making it easier and more efficient for providers to get their
specimens in the hands of researchers who need them. Our iSpecimen Marketplace technology makes it as easy to find specimens for research
as it is to find flights on a travel website. We have adopted many of the same ease-of-use characteristics of these business-to-consumer,
or B2C, marketplaces, from simple guided searches to the ability to refine search criteria with sliders and checkboxes, to the ability
to add chosen items to a cart in order to purchase them, to online order management. Our two-sided marketplace platform makes it easy
for researchers and healthcare providers to connect and transact, introducing efficiencies into what is otherwise a very time- consuming
and manual process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our iSpecimen Marketplace technology is groundbreaking
in the human biospecimen procurement space. In a world where there are thousands of biospecimen providers who typically rely upon e-mail
and spreadsheets to communicate with customers to manage the bioprocurement process, our iSpecimen Marketplace offers a more efficient
user experience to life science researchers who are looking for better ways to access research subjects, specimens, and data, and to
healthcare provider organizations, who are looking to realize their missions of supporting research while augmenting their bottom line.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Planned Developments of our Marketplace</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the iSpecimen Marketplace currently supports our business model
of providing access to search, find, and acquire human biospecimens and associated data from &ldquo;inquiry to invoice&rdquo; and positions
us for future expanded business model exploration, there are a number of areas in which the iSpecimen Marketplace functionality could
be enhanced to better support our stakeholders, including our prospects and customers, iSpecimen sales and operations staff, and our
supply partners. We believe with additional investment in technology development resources, we could make significant progress in scaling
our iSpecimen Marketplace and, in addition to increased patient and specimen data integration, we expect to continue to improve the matchmaking
across the platform and have capabilities such as more direct support for our prospective collections, deeper search and workflow capabilities,
increased automation, and direct pricing availability in the platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As investment allows, we plan to continue to
better connect healthcare researchers with our network of suppliers to enable the acquisition of human biospecimens and data to help
accelerate research and expand the impact of our iSpecimen Marketplace platform from &ldquo;inquiry to invoice&rdquo; through the following
key approaches:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Enhance the customer experience</I>. By working
    with our prospects and customers to understand their needs, we strive to provide a platform that more easily enables them to specify
    and find human biospecimens and data that meet the requirements of their research.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Increase our supplier engagement</I>. By continuing
    to engage with our supply partners to deliver solutions that make their interactions with us more fulfilling, we become more seamlessly
    integrated into their workflows and daily operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Improve operational efficiency</I>. By measuring
    the results of our operational workflows, we endeavor to reduce the friction and manual efforts in our processes and systems.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to prioritize and release updated
versions of the iSpecimen Marketplace platform in alignment with these areas and believe that continuing to focus on these approaches
will enable us to scale our business model more effectively. As part of this continued platform evolution, iSpecimen continues to explore
adjacencies that leverage the platform including a data as a product model.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Technology</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Technology Components</I></B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The iSpecimen Marketplace technology is comprised
of four major functional areas: search; workflow; data; and administrative, compliance and reporting. We continue to invest in the evolution
of these areas to improve customer and supplier engagement with the platform; provide operational efficiencies for our suppliers, our
customers, and our internal operations; and increase the liquidity of products and services obtained through the platform. Our core business
objective is to retain and grow both researcher and supplier usage of our platform to support biospecimen procurement, as well as to position
our Company to explore other adjacent business opportunities that can benefit from the use of the iSpecimen Marketplace.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The legacy iSpecimen Marketplace has been operational
for many years as an external-facing platform designed to facilitate search and matching between researchers and suppliers. While it supported
the Company&rsquo;s growth and market presence, its architecture led to increasing operational complexity and fragmentation across commercial,
data, and fulfillment processes. Recently, the Company made a strategic investment in a new technology platform built on its SalesStack
solution to modernize the legacy system.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This new system introduces a cloud-native, next-generation
architecture, providing a more secure, scalable, and efficient foundation for the Marketplace. Key improvements include the adoption of
Infrastructure-as-Code which enables automated, consistent, and more secure infrastructure deployment. In addition, the platform establishes
unified storage and workflow management, centralizing code and services to reduce silos, improve maintainability, and lower technical
debt. The new architecture also creates a future-ready foundation with streamlined deployment capabilities, automated security controls,
and seamless integration across major cloud environments, including AWS, GCP, and Azure.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Building the Marketplace on SalesStack is an important
step in unifying the Company&rsquo;s commercial, operational, and data capabilities within a single, integrated system. This approach
improves coordination across customer acquisition, order fulfillment, supplier engagement, and compliance management, enabling greater
operational efficiency and scalability.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has successfully transitioned its
core capabilities&mdash;including workflow management, data infrastructure, and administrative, compliance, and reporting functions&mdash;from
the legacy platform into the new system. These components now provide a more streamlined and integrated environment for managing customer
demand, supplier engagement, regulatory requirements, and operational reporting.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The next phase of development focuses on migrating
and integrating specimen and patient data into the new platform to further enable and enhance search capabilities. Once completed, this
will allow for more effective matching between researcher needs and available supply, strengthening the overall functionality of the Marketplace.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The Company continues to invest in advancing its technology to improve
engagement across researchers and suppliers, drive operational efficiencies, and increase liquidity within the Marketplace. The modernized
platform establishes a scalable and flexible foundation that supports both current operational needs and future innovation.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Search</I>. The iSpecimen Marketplace enables
    researchers to identify and procure subjects, specimens, and associated data as part of an integrated, end-to-end platform.</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The iSpecimen Marketplace enables researchers
    to identify and procure subjects, specimens, and associated data as part of an integrated, end-to-end platform.</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Researchers can define subject and sample criteria
    within the Marketplace and access information derived from medical records across iSpecimen&rsquo;s healthcare provider network. This
    supports the creation of customized patient and specimen cohorts aligned with specific study requirements. Users can review available
    options, refine their criteria, and select specimens that meet their needs, or submit requests for iSpecimen to source specimens and data
    that are not immediately available.</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to current availability, the platform
    provides visibility into expected specimen availability based on historical data trends. These insights help researchers assess feasibility,
    plan studies, and make more informed budgeting decisions.</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rather than functioning solely as a directory
    or referral tool, the Marketplace integrates discovery, selection, and procurement into a unified workflow. Researchers can identify relevant
    specimens, initiate requests, and move efficiently toward fulfillment within a single system.</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By combining data-driven insights with streamlined
    workflows and intuitive user experiences, the Marketplace supports efficient collaboration between researchers and suppliers while enabling
    scalable biospecimen procurement.</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Workflow.&nbsp;</I>Our workflow engine supports
    the unique bioprocurement workflows of our suppliers, customers, and internal iSpecimen operations users. For our suppliers, our
    ability to easily integrate into their environments and automate key parts of their bioprocurement workflow enables us to maintain
    a level of engagement and responsiveness necessary to successfully deliver on specimen requests from our research customers. We make
    it easy for suppliers to list their specimens in our iSpecimen Marketplace by receiving their data in the most commonly used data
    transmission formats for healthcare data, such as HL7 feeds (a healthcare data interchange standard), JSON files (a standard data
    interchange format), and CSV files (a comma separated values file used for tabular data), and then by harmonizing this data into
    standard terminology sets that allows their specimens to be searchable by our research customers. We provide these onboarding services
    at no charge to our supply partners. Additionally, our iSpecimen Marketplace technology enables suppliers to track and manage all
    of their specimen requests from feasibility assessment through the ordering and fulfillment process in a single web application,
    thereby streamlining their bioprocurement workflow. Because the work that we do with our suppliers is often a secondary concern to
    their primary mission of providing patient care, we believe that seamlessly integrating into their workflow is critical to its use
    and ongoing success.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Data.&nbsp;</I>We power search and orchestrate
    the procurement workflow through our ability to acquire, ingest, generate, and use big data from our healthcare provider partners.
    Working with a global, centralized set of healthcare providers, we receive this data in a variety of different formats and quality
    levels. We de-identify, normalize, and harmonize our supplier network&rsquo;s data for usage in our iSpecimen Marketplace, ensuring
    the highest level of patient privacy and compliance with HIPAA and other applicable regulations that govern the research use of patient
    specimens and data.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Administrative, Compliance, and Reporting.</I>&nbsp;Administrative,
    compliance, and reporting functions are critical components to enable users to properly evaluate and manage the bioprocurement process.
    Our administrative capabilities include functions such as user management to assign users and roles and password management to ensure
    passwords are updated regularly, among other capabilities. Compliance management includes manual and technology-based processes that
    allow iSpecimen to track and manage unique regulatory and legal requirements across customers and suppliers (such as consent requirements
    versus consents granted, required specimen and data uses versus allowable specimen and data uses, resale or distribution requirements
    versus resale or distribution rights) to make sure that customer requirements and supplier requirements match before transferring
    specimens and data. Additionally, we conduct regular audits of supply sites capabilities and confirm that supply sites have Institutional
    Review Board (or equivalent) protocols in place where required by law. Our reporting tools turn operational data into useful information
    by enabling users to view operational data in tables and other visualizations. Together, they help manage and streamline administrative,
    compliance, and operational functions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Technology Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The iSpecimen Marketplace software was developed
over ten years with more than 80 staff years invested in research, development, implementation, maintenance and support. It comprises
an orchestration of software as a service, or SaaS, solutions, commercial and open-source components, and custom developed software deployed
in the cloud on a third-party hosting platform built and maintained through a combination of full- time staff and outsourced partners.
The team uses agile practices to develop and improve the platform. We continue to enhance and improve the performance, functionality,
and reliability of the iSpecimen Marketplace platform based on a user-informed roadmap that is actively updated based on internal and
external feedback aligned with our goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The iSpecimen Marketplace relies on third parties
for certain technology to support development, delivery, and operations of the platform including product management, software development,
cloud hosting, data processing, content mapping, and security services. iSpecimen uses software (including source code) and other materials
that are distributed under a &ldquo;free,&rdquo; &ldquo;open source,&rdquo; or similar licensing model, including software distributed
under the Apache License, Version 2.0, The MIT License, Mozilla Public License 2.0 (MPL-2.0), GNU General Public License version 2, GNU
Lesser General Public License version 2.1, Eclipse Public License 1.0 (EPL-1.0), Common Development and Distribution License 1.0. In
addition, iSpecimen uses software and services from commercial providers. We do not believe any of them are not generally commercially
available to us from other parties. iSpecimen does not have any technology licensing contracts signed within the last two years upon
which our business is substantially dependent. We continue to evaluate partners whose capabilities can help us deliver our iSpecimen
Marketplace solution in areas such as functionality, efficiency, and security and expect to continue to leverage and consider additional
third-party capabilities in our ongoing Marketplace development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Competitive Advantages</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When successfully implemented, online marketplaces
are a highly efficient supply chain that offer many advantages to both suppliers and customers, including lower costs, reduced procurement
timeframes, increased revenue (for suppliers), increased access to a large and growing supply network (for customers), and reduced risks.
While our iSpecimen Marketplace is providing these benefits now, we believe they will become even more apparent when the iSpecimen Marketplace
achieves greater capabilities and scale as additional investment is made into the platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Products and Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The iSpecimen Marketplace currently supports
the supply chain management and bioprocurement process for specimens and associated data. We derive our revenue by procuring specimens
from our healthcare provider network and then distributing these annotated biospecimens to our research client base. Revenue flows from
the researchers who pay our Company to provide the specimens and we share that revenue back with the healthcare providers who supplied
them. Revenue share back to the supplying organization is generally 20% to 50%, depending upon the sample type, collection requirements,
and data provided. We are flexible and allow our suppliers to work with us using a number of revenue share constructs, including a fixed
percent revenue share arrangement (whereby we share a fixed percentage of the revenue back with them), a fixed pricing schedule (whereby
they set their pricing per specimen type), or on a project-based pricing (whereby the supply site sets fees on a per project basis).
We have derived substantially all of our revenue from annotated biospecimen procurement and to date, have not charged our customers or
suppliers fees for the use of the iSpecimen Marketplace platform, or for marketing, sales, contracting, or compliance functions that
we provide as part of the specimen procurement process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We generally operate in a &ldquo;just in time&rdquo;
fashion, meaning we procure specimens from our suppliers and distribute specimens to our customers after we obtain an order for specimens
from a research client. Generally, we do not speculatively purchase and bank samples in anticipation of future, unspecified needs. We
believe our approach offers many advantages over a more traditional inventory-based supplier business model where biorepositories take
inventory risks, and where turnover and cash conversion cycles can be lengthy, depending on market demand for certain specimen types.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, we provide access to the following
types of human biospecimens from healthy and diseased-state subjects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Biofluids &mdash; such as whole blood, plasma, serum,
    urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Solid tissue &mdash; such as fresh, fixed, and cryopreserved
    tissue; and formalin-fixed paraffin embedded blocks, slides, and curls; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Hematopoietic stem and immune cells &mdash; such as
    bone marrow, cord blood, whole blood, or sub- components of these tissues such as peripheral blood mononuclear cells (including normal
    or mobilized leukapheresis collections) and other isolated cell types (CD34+,T cells, NK cells, B cells, and monocytes).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For each of the biospecimen types, we offer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Remnant specimens &mdash; specimens collected originally
    for clinical testing purposes but are no longer needed for clinical care of that patient. These samples typically are sourced from
    clinical laboratories and pathology laboratories prior to their disposal; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Research use only specimens &mdash; specimens collected
    specifically for research via a direct intervention with a research subject, under a protocol that has been reviewed and approved
    by an ethics committee such as an Institutional Review Board (&ldquo;IRB&rdquo;) and with such research subject&rsquo;s consent.
    These samples are typically sourced at healthcare providers or commercial partners that are a part of our supply network.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cross product of all these categories (i.e.,
remnant or research use only and biofluids, tissues, or hematopoietic stem or immune cells) describes the product types we use to track
and manage the business. These groupings include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Remnant biofluids &mdash; These leftover clinical samples are procured from our clinical lab partners and are typically available days after specimen collection. They are generally priced to the researcher per specimen, depending upon specimen type, rarity, and requested data. These specimens contributed to approximately 11% of our revenue in 2024 and 23% of our revenue for the twelve months ended December 31, 2025, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Remnant tissue &mdash; These leftover anatomic pathology samples are procured from our pathology lab partners and typically are available years after they were first collected for clinical care. They are generally priced depending upon specimen type, rarity, and requested data.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Remnant hematopoietic stem and immune cells &mdash;
    Remnant hematopoietic stem and immune cells includes bone marrow, cord blood, whole blood, or their viable cellular components, that
    are left over from a clinical testing process. These samples may be obtained from clinical and anatomic pathology labs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Next generation sequenced (&ldquo;NGS&rdquo;) tissues
    &mdash; NGS tissues include various cancer types that have been fully DNA/RNA sequenced to identify specific biomarkers of interest.
    The tissues screened are tumor only FFPE specimens. Results are analyzed and paired with clinical annotation to create a robust data
    package that has some utility even without the need for the specimen itself. Tissues used for the program are a combination of remnant
    waiver of consent tissue blocks along with RUO fully consented blocks.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Research use only biofluids &mdash; Research use only biofluids are collected directly from subjects, with their consent, and under an IRB (or equivalent) protocol. We obtain these samples via a variety of sources, including our biorepository and clinical research center partners. They are generally priced to the researcher per collection, depending upon specimen type, rarity, and requested data. These specimens contributed to approximately 49% of our revenue in 2024 and 56% of our revenue for the twelve months ended December 31, 2025, respectively.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Research use only tissue &mdash; Research use only tissues are collected directly from subjects, with their consent, and under an IRB (or equivalent) protocol. They are typically collected during a clinically required surgical procedure. We obtain these specimens from our biorepository partners, anatomic pathology laboratories, or clinical research centers that have relationships with surgical facilities. These samples are priced to the researcher per sample, depending upon specimen type, rarity, and requested data. These specimens contributed to approximately 39% of our revenue in 2024 and 18% of our revenue for the twelve months ended December 31, 2025, respectively.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Research use only hematopoietic stem and immune cells &mdash; Research use only hematopoietic stem and immune cells includes bone marrow, cord blood, whole blood, or their cellular components, which are collected from subjects with their consent and under an IRB (or equivalent) protocol. Some of the aforementioned products are collected from healthy subjects or diagnosed (diseased) subjects and may be offered to researchers in fresh or cryopreserved format. They are prospectively collected primarily from our blood donor center partners or picked from banked inventory maintained by our supply site partners. The collection of these samples may require subjects to undergo apheresis procedures, bone marrow extraction procedures, and/or hematopoietic stem cell (HSC) mobilization therapies. These products are generally priced to the researcher per collection depending upon collection type, specimen type, rarity (subject phenotype or attributes selected), required procedures, and requested data. These specimens accounted for approximately 1% of our revenue in 2024 and 3% of our revenue for the twelve months ended December 31, 2025, respectively.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For each of these product types, biospecimens
may already exist in laboratory archives or banked in our network of biorepositories (&ldquo;banked&rdquo;) or may be collected in the
future from our network of healthcare providers and commercial specimen providers (&ldquo;prospectively-collected&rdquo; or &ldquo;custom
collections&rdquo;).</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Supply Partners</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Critical to the success of the iSpecimen Marketplace
is the network of healthcare providers who make their patients, samples, and data available to researchers. This supply network was built
over a ten-year period and as of December 31, 2025, our supply network consisted of approximately 73 unique healthcare organizations
and biospecimen providers under agreement, including healthcare systems, community hospitals, clinics, private practice groups, commercial
laboratories, blood centers, commercial biobanks, clinical research sites, and cadaveric donation centers.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our suppliers are located in fourteen (14) countries across the Americas,
Europe, and Asia and our cost of revenue for the years ended December 31, 2025 and 2024, break out as follows geographically:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Americas</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">68.92</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">66.19</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Europe, Middle East and Africa</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31.25</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27.24</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Asia Pacific</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.17</TD><TD STYLE="text-align: left">)%</TD><TD><SUP>1</SUP></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.57</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>



<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD>
    <TD STYLE="text-align: justify">includes supplier credits received during the year</TD></TR>
  </TABLE>


<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was one supplier that accounted for 12% of our total cost of
revenue during the year ended December 31, 2025. There was one supplier that accounted for 11.3% of our total cost of revenue during the
year ended December 31, 2024.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each supplier organization may give us access
to one or more of the following environments within their organization where specimens may be obtained:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Clinical labs &mdash; This environment provides access to remnant biofluids and is typically found in hospitals, commercial laboratories, clinics, and private practice groups. As of December 31, 2025, approximately 12 of our healthcare supply sites provided us with access to remnant biofluids originating in clinical labs;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pathology labs &mdash; This environment provides access to remnant tissue and remnant hematopoietic stem and immune cells and typically exists within hospitals or commercial laboratories. As of December 31, 2025, approximately one (1) of our healthcare supply sites provided us with access to remnant tissue or cells originating in pathology labs;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Biorepositories &mdash; These organizations typically reside within larger healthcare systems or commercial organizations. Generally, they collect and store specimens for unspecified future research purposes. As of December 31, 2025, approximately 16 of our supply sites provided us with access to specimens stored in biorepositories;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Blood donor centers &mdash; These organizations typically collect large volumes of blood and derivatives for therapeutic or research purposes. They own and operate donor centers and may manufacture broad selection of isolated cell types (fresh or cryopreserved) from consented donors for research use. As of December 31, 2025, two (2) of our supply sites provided us with access to large volume blood products;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cadaveric donation centers &mdash; These organizations receive whole cadavers and provide access to cadaveric tissues, biofluids, and stem cells, specifically for research purposes. As of December 31, 2025, one (1) of our supply sites provided us with cadaveric tissues and biofluids; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Clinical research centers &mdash; These organizations generally reside within healthcare facilities such as hospitals or clinics, or they operate as standalone entities providing access to subjects for research programs. Subjects may be approached and consented to provide specimens when they are in for healthcare appointments (i.e. patient encounters) or may be called in to specifically participate in research projects. As of December 31, 2025, approximately 41 of our healthcare supply sites provided us with access to patients directly from over thousands hospitals and thousands of clinics and practice groups.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></DIV>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supply sites may provide specimens from one
or all these environments, depending on their practices and capabilities. Each supply site can select how it will work with our
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to obtaining specimens and data directly
from healthcare organizations, we work with several commercial biobanks and biospecimen brokers who have their own network of healthcare
provider supply partners and wish to make their samples available to our research clients as well. While these organizations are generally
considered our competitors, they are willing to work with us because we provide value by acting as both a distribution channel for them
and a supply partner to them to increase their revenues. Moreover, the inclusion of competitors&rsquo; specimens in our iSpecimen Marketplace
platform further strengthens our competitive position and value to our customers by further de- fragmenting our customers&rsquo; buying
experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Customers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our customer base is primarily comprised of three
main segments: biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. As of December 31, 2025,
we had distributed our specimens to approximately 776 customers, such as the Centers for Disease Control and Prevention. Since entering
the regenerative medicine market late 2019, we have acquired 33 customers representing 0.7% of our total revenue both in 2024 and in
2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From our inception through December 31, 2025, we had distributed more
than 218,000 specimens to 23 countries and our geographical revenues distribution for the years ended December 31, 2025 and 2024 were
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Americas</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">94.74</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">85.13</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Europe, Middle East and Africa</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.88</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.71</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Asia Pacific</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.38</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.16</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2025, there was
one customer that accounted for approximately 20% of our total revenue generated. During the year ended December 31, 2024, there was one
customer that accounted for approximately 29% of our total revenue generated. We continuously engage with all customers when we receive
inbound requests from them, whether they are within or outside of the Americas. Year-over-year, our top customers have been different
because their specimen needs tend to be project-based and depending upon where they are in their research and development cycle, they
may not need large numbers of specimens each year. During the year, our customer retention rates are moderate, with 12 of our top 25 customers
(48%) in the year ended December 31, 2024 also procuring specimens in the year ended December 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Biospecimens have broad utility within the healthcare
and life science industries, as they are collected and used throughout nearly every stage of diagnostic and therapeutic product discovery
and development. For diagnostic products, they are used consistently for preclinical discovery, clinical validation, and post-market
validation, as well as surveillance. For therapeutic products, these samples are most often used during preclinical research involving
drug target identification and validation, compound screening, lead optimization, predictive toxicology, and pharmacokinetic studies.
They are also used for biomarker companion diagnostic discovery and development, which has been shown to reduce the costs of drug clinical
trials by 30 to 60% according to Ark Research. In the case of regenerative medicine applications, hematologic samples are used for research
and development of engineered cell therapies (e.g. CAR-T, CAR-NK), stem cell therapies (e.g. hematopoietic stem cells, mesenchymal stem
cells), exosome therapies, identification of cell immunophenotypes for allogeneic therapies, and for developing and scaling-up cell therapy
manufacturing processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given recent advances in technology that now
allow for the identification of molecular determinants of disease, the role of the patient&rsquo;s biospecimen has become even more important
in all these endeavors and is essential to the development of precision medicine. This pursuit of precision medicine by the healthcare
and life science industries has further increased the already high demand for human biospecimens and the clinical data that describe
them.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being an Emerging Growth Company and a Smaller
Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We qualify as an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). As an &ldquo;emerging growth company&rdquo;
we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include,
but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            option to present only two years of audited financial statements and only two years of related
                                            &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
                                            in this prospectus;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Not
                                            being required to comply with the auditor attestation requirements of Section 404 of the
                                            Sarbanes- Oxley Act of 2002, as amended (the &ldquo;Sarbanes-Oxley Act&rdquo;);</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Not
                                            being required to comply with any requirements that may be adopted by the Public Company
                                            Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the
                                            auditor&rsquo;s report providing additional information about the audit and the financial
                                            statements (i.e., an auditor discussion and analysis);</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.4pt; text-indent: -10pt">&nbsp;&nbsp;</P>
</DIV>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reduced
                                            disclosure obligations regarding executive compensation in our periodic reports, proxy statements
                                            and registration statements; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exemptions
                                            from the requirements of holding a nonbinding advisory vote on executive compensation and
                                            stockholder approval of any golden parachute payments not previously approved.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of these provisions until
December 31, 2026, which is the last day of our fiscal year following the fifth anniversary of the consummation of our initial public
offering (&ldquo;IPO&rdquo;). However, if any of the following events occur prior to the end of such five-year period, (i) our annual
gross revenue exceeds $1.235 billion, (ii) we issue more than $1.0 billion of non-convertible debt in any three-year period, or (iii)
we become a &ldquo;large accelerated filer,&rdquo; (as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;)), we will cease to be an emerging growth company prior to the end of such five-year period. We will be deemed
to be a &ldquo;large accelerated filer&rdquo; at such time that we (a) have an aggregate worldwide market value of common equity securities
held by non-affiliates of $700.0 million or more as of the last business day of our most recently completed second fiscal quarter, (b)
have been required to file annual and quarterly reports under the Exchange Act for a period of at least 12 months and (c) have filed
at least one annual report pursuant to the Exchange Act. Even after we no longer qualify as an emerging growth company, we may still
qualify as a &ldquo;smaller reporting company,&rdquo; which would allow us to take advantage of many of the same exemptions from disclosure
requirements including reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and
proxy statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have elected to take advantage of certain
of the reduced disclosure obligations in the registration statement of which this prospectus is a part (the &ldquo;Registration Statement&rdquo;)
and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide
to our stockholders may be different than what you might receive from other public reporting companies in which you hold equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also a &ldquo;smaller reporting company&rdquo;
as defined in the Exchange Act, and have elected to take advantage of certain of the scaled disclosures available to smaller reporting
companies. To the extent that we continue to qualify as a &ldquo;smaller reporting company&rdquo; as such term is defined in Rule 12b-2
under the Exchange Act, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an &ldquo;emerging
growth company&rdquo; may continue to be available to us as a &ldquo;smaller reporting company,&rdquo; including exemption from compliance
with the auditor attestation requirements pursuant to SOX and reduced disclosure about our executive compensation arrangements. We will
continue to be a &ldquo;smaller reporting company&rdquo; until we have $250 million or more in public float (based on our common stock)
measured as of the last business day of our most recently completed second fiscal quarter or, in the event we have no public float (based
on our common stock) or a public float (based on our common stock) that is less than $700 million, annual revenues of $100 million or
more during the most recently completed fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the JOBS Act provides that an emerging
growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected
to take advantage of this extended transition period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Nasdaq Compliance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 4, 2025, we received a written notice
from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) indicating that we were not in compliance
with the minimum stockholders&rsquo; equity requirement under Nasdaq Listing Rule 5550(b)(1). As reported in our Quarterly Report on
Form 10-Q for the period ended March 31, 2025, we had stockholders&rsquo; equity of $1,668,513, which is below the required $2.5 million.
Nasdaq further noted that we did not meet the alternative continued listing criteria related to market value of listed securities or
net income from continuing operations. The notice had no immediate effect on the listing or trading of our common stock, which continues
to trade on the Nasdaq Capital Market under the symbol &ldquo;ISPC&rdquo;. On November 28, 2025, we received a letter from Nasdaq notifying
us that, based on our Quarterly Report on Form 10-Q for the period ended September 30, 2025, which reported stockholders&rsquo; equity
of $3,072,711, we have regained compliance with the applicable continued listing requirements under Nasdaq Listing Rules 5550(b)(1),
5550(b)(2), and 5550(b)(3), and the matter is now closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Separately, on November 19, 2025, we received a written notice from Nasdaq indicating that the closing bid price of our common stock had
been below the minimum $1.00 per share required under Nasdaq Listing Rule 5550(a)(2) for the prior 30 consecutive business days and that,
as a result, we were not in compliance with the minimum bid price requirement. On April 27, 2026, the Company effected a 1-for-40 reverse
stock split of its outstanding common stock (the &ldquo;Reverse Stock Split&rdquo;), and its common stock began trading on a split-adjusted
basis on April 28, 2026. On May 12, 2026, we received a letter from Nasdaq notifying us that, for the last 10 consecutive business days
from April 28, 2026 to May 11, 2026, the closing bid price of our common stock had been at $1.00 per share or greater, and accordingly,
we have regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Reverse Stock Split</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2026, the Company filed a Fifth Amended and Restated Certificate
of Incorporation with the Secretary of State of the State of Delaware, which, among other things, effectuated the Reverse Stock Split
at a ratio of 1-for-40. The Reverse Stock Split became effective at 4:30 p.m. Eastern Time on April 27, 2026. As a result of the Reverse
Stock Split, every 40 shares of the Company&rsquo;s issued and outstanding common stock were automatically combined into one share of
common stock, without any change in the par value per share. No fractional shares were issued in connection with the Reverse Stock Split;
any fractional share that would otherwise have resulted was rounded up to the nearest whole share. Immediately prior to the effectiveness
of the Reverse Stock Split, the Company had 52,639,796 shares of common stock issued and outstanding. Following the Reverse Stock Split,
the Company had approximately 1,316,032 shares of common stock issued and outstanding. The Company&rsquo;s common stock continues to trade
on the Nasdaq Capital Market under the symbol &ldquo;ISPC&rdquo; and has the CUSIP number 45032V306.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, proportionate adjustments were made to (i) the per share
exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of
common stock, (ii) the number of shares of common stock issuable upon the vesting of outstanding restricted stock units, and (iii) the
number of shares reserved for issuance pursuant to the Company&rsquo;s equity incentive plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were formed as a Delaware corporation in July
2009. Our headquarters are in Woburn, MA, and our principal executive offices are located at 8 Cabot Road, Suite 1800, Woburn, MA 01801,
and our telephone number is (781)301-6700. Our website address is&nbsp;<I>www.ispecimen.com</I>. The information contained in, or accessible
through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as
an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></DIV>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.0; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock Offered by Selling Stockholders:</B></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">488,290
    shares</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
    of Common Stock outstanding after completion of this offering:</B></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; font-size: 10pt">1,925,447
    shares (1)</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of Proceeds:</B></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
    will not receive any proceeds from the sale of the Shares and Warrant Shares by the Selling Stockholders. We may, however, receive
    nominal proceeds from any cash exercise of the Pre-Funded Warrants. Assuming the cash exercise in full of all outstanding Pre-Funded
    Warrants at the exercise price of $0.0001 per share, we would receive aggregate gross proceeds of approximately $40.00. The Pre-Funded
    Warrants are exercisable on a cashless basis, and we expect that the Selling Stockholders will exercise the Pre-Funded Warrants on
    a cashless basis, in which case we would not receive any proceeds from such exercise. Any proceeds we receive from the cash exercise
    of the Pre-Funded Warrants will be used for working capital and general corporate purposes. The Selling Stockholders will pay any
    agents&rsquo; commissions and expenses they incur for brokerage, accounting, tax or legal services or any other expenses that they
    incur in disposing of the shares of common stock. We will bear all other costs, fees and expenses incurred in effecting the registration
    of the shares of common stock covered by this prospectus and any prospectus supplement, including all registration and filing fees,
    SEC filing fees and expenses of compliance with state securities or &ldquo;blue sky&rdquo; laws.</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
    Symbol</B></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ISPC</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    Factors:</B></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    investment in our company is highly speculative and involves a significant degree of risk. See &ldquo;Risk Factors&rdquo; and other
    information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in shares
    of our common stock.</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The number of shares of our common stock outstanding prior to and
                                                                                                                                                     after this offering is based on 1,437,157 shares of common stock outstanding as of May 29, 2026, and excludes (a) outstanding stock
                                                                                                                                                     options to purchase 73 shares of common stock at an average price of $2,012.40 per share; (b) outstanding restricted stock units of
                                                                                                                                                     0.22 shares issuable upon vesting; (c) outstanding warrants to purchase 128 shares of common stock at an average price of $7,804.88
                                                                                                                                                     per share; and (d) 403,088 shares of common stock issuable upon exercise of Pre-Funded Warrants issued in the May 2026 Private
                                                                                                                                                     Placement.</P></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.0">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>An investment in our
securities involves a high degree of risk. Before making an investment decision, you should carefully consider all risk factors set forth
in any applicable prospectus supplement and the documents incorporated by reference in this prospectus, including the factors discussed
under the heading &ldquo;Risk Factors&rdquo; in our most recent annual report on Form 10-K or any updates in our quarterly reports on
Form 10-Q or current reports on Form 8-K, which may be amended, supplemented or superseded from time to time by the other reports we file
with the SEC in the future or by information in the applicable prospectus supplement. See &ldquo;Information Incorporated by Reference.&rdquo;
Our business, prospects, financial condition or operating results could be harmed by any of the risks described, as well as other risks
not known to us or that we consider immaterial as of the date of this prospectus. The trading price of our securities could decline due
to any of these risks, and, as a result, you may lose all or part of your investment.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Sales of a substantial
number of shares by the Selling Stockholders may adversely affect the market price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The sale of a substantial
number of shares of our common stock in the public market by the Selling Stockholders, or the perception that such sales may occur, could
materially and adversely affect the market price of our common stock and could impair our ability to raise capital through the sale of
additional equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This prospectus relates to the resale, from time to time, of up to
an aggregate of 488,290 shares of our common stock by the Selling Stockholders, which include (i) 85,202 shares of common stock issued
in the May 2026 Private Placement, and (ii) 403,088 shares of common stock issuable upon exercise of Pre-Funded Warrants issued in the
May 2026 Private Placement. The resale of these shares into the market could result in increased volatility and downward pressure on the
trading price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Given the number of shares that may be resold under the registration
statement of which this prospectus forms a part, any such sales by the Selling Stockholders could cause the market price of our common
stock to decline significantly. Additionally, the Selling Stockholders may sell their shares at any price and at any time, which could
cause our share price to fluctuate and make it more difficult for us to raise additional capital or for investors to sell their shares
at favorable prices. If these shares are sold in significant amounts, or if investors anticipate that a large amount of shares will be
sold, it could result in a decline in the price of our common stock, increased volatility and reduced liquidity in our stock.</P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We are required
to seek stockholder approval to issue shares in excess of the Exchange Cap (as defined below), and there can be no assurance that such
approval will be obtained.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the terms
of the Purchase Agreement and the Pre-Funded Warrants, the aggregate number of shares of Common Stock issuable to the Investors in the
May 2026 Private Placement (including upon exercise of the Pre-Funded Warrants and giving effect to any anti-dilution and price adjustment
provisions thereunder) is subject to a cap of 19.99% of the Company&rsquo;s outstanding Common Stock immediately prior to the execution
of the Purchase Agreement (the &ldquo;Exchange Cap&rdquo;), until such time as we obtain the approval of our stockholders as required
under applicable Nasdaq Listing Rules. We are obligated to seek such stockholder approval; however, there can be no assurance that our
stockholders will approve the issuance of shares in excess of the Exchange Cap. If stockholder approval is not obtained, the Selling Stockholders
will be unable to exercise the Pre-Funded Warrants in full to the extent such exercise would result in the issuance of shares in excess
of the Exchange Cap, and certain anti-dilution adjustments contained in the Pre-Funded Warrants will be inoperative with respect to shares
above the Exchange Cap. Any such limitation could adversely affect the rights of the Selling Stockholders and our ability to comply with
our obligations under the Purchase Agreement and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>The Selling Stockholders
acquired the Shares and Pre-Funded Warrants at a cost basis below the current market price of our common stock, and may have an incentive
to sell at prices below those acceptable to other investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Selling Stockholders
acquired the Shares at a purchase price of $5.12 per Share and the Pre-Funded Warrants at a purchase price of $5.1199 per Pre-Funded Warrant
(reflecting a per share effective cost basis of approximately $5.12). As a result, the Selling Stockholders may realize a profit on the
sale of shares of our common stock at prices that are below the current market price, and may therefore have an incentive to sell their
shares at prices below those at which stockholders who purchased shares in the open market would be willing to sell. Sales by the Selling
Stockholders at prices below the prevailing market price could adversely affect the market price of our common stock and make it more
difficult for other stockholders to sell their shares at prices they consider acceptable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>The anti-dilution
and price adjustment provisions in the Pre-Funded Warrants could result in additional dilution beyond the 488,290 shares registered hereby.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Pre-Funded Warrants
contain anti-dilution and price adjustment provisions that may, in certain circumstances, result in the issuance of additional shares
of common stock beyond the 488,290 shares registered for resale under this prospectus. Any additional shares issuable as a result of such
adjustments are not reflected in the number of shares registered hereby and may require additional registration or an amendment to this
registration statement. The issuance of additional shares pursuant to these provisions would further dilute the ownership interests of
existing stockholders, could adversely affect the market price of our common stock and may impair our ability to raise additional capital
on favorable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>A registration
default under the Registration Rights Agreement could result in liquidated damages obligations that would adversely affect our cash position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the Registration
Rights Agreement, we are obligated to file and maintain the effectiveness of a registration statement covering the resale of the Shares
and Warrant Shares. If we fail to satisfy our registration obligations under the Registration Rights Agreement, including by failing to
file or obtain or maintain the effectiveness of the registration statement within specified timeframes, we may be required to pay liquidated
damages to the Selling Stockholders. Any such liquidated damages payments would have an adverse effect on our cash position and could
divert funds from our operations and working capital needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>The number of shares
registered for resale is significant relative to our public float, which could create substantial overhang and depress the price of our
common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The 488,290 shares of
common stock registered for resale under this prospectus represent a significant percentage of our outstanding shares and our public float.
The existence of a large number of shares eligible for sale in the public market, or the perception that such sales could occur, may create
significant overhang on the market price of our common stock and may discourage potential investors from purchasing our common stock.
This overhang effect could depress the trading price of our common stock and impair our ability to raise additional equity capital on
favorable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>The SEC may take
the position that this offering is a primary offering by or on behalf of the Company, which could result in a reduction in the number
of shares registered for resale or delay the Selling Stockholders&rsquo; ability to resell.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The SEC may take the
position that this offering should be characterized as a primary offering by or on behalf of the Company rather than a secondary offering
on behalf of the Selling Stockholders under Rule 415 of the Securities Act. If the SEC were to take such a position, it could result in
a reduction or cutback of the number of shares registered for resale under this prospectus, which could delay or impair the ability of
the Selling Stockholders to resell their shares and could adversely affect the liquidity of our common stock. Any such cutback could also
require us to file additional registration statements to cover the excluded shares, which would result in additional expenses and delays.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;<B><A NAME="a_005"></A>USE
OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any of the proceeds from the
sale of the Shares or Warrant Shares by the Selling Stockholders pursuant to this prospectus. We may, however, receive nominal proceeds
from any cash exercise of the Pre-Funded Warrants. Assuming the cash exercise in full of all outstanding Pre-Funded Warrants at the exercise
price of $0.0001 per share, we would receive aggregate gross proceeds of approximately $40.00. The Pre-Funded Warrants are exercisable
on a cashless basis, and we expect that the Selling Stockholders will exercise the Pre-Funded Warrants on a cashless basis, in which case
we would not receive any proceeds from such exercise. Any proceeds we receive from the cash exercise of the Pre-Funded Warrants will be
used for working capital and general corporate purposes. The Selling Stockholders will pay any agents&rsquo; commissions and expenses they incur
for brokerage, accounting, tax or legal services or any other expenses that they incur in disposing of the shares of common stock. The
Selling Stockholders will pay any agents&rsquo; commissions and expenses they incur for brokerage, accounting, tax or legal services or
any other expenses that they incur in disposing of the shares of common stock. We will bear all other costs, fees and expenses incurred
in effecting the registration of the shares of common stock covered by this prospectus and any prospectus supplement. These may include,
without limitation, all registration and filing fees, SEC filing fees and expenses of compliance with state securities or &ldquo;blue
sky&rdquo; laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_014"></A>MAY</B></FONT><B>
2026 PRIVATE PLACEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On May 8, 2026, we entered
into the Purchase Agreement with certain accredited investors (the &ldquo;Investors&rdquo;), pursuant to which the Company agreed to issue
and sell 488,281 shares of common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo; or &ldquo;Shares&rdquo;), at a purchase
price of $5.12 per Share. In lieu of Shares that would otherwise result in a purchaser&rsquo;s beneficial ownership exceeding 4.99% of
the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such Shares, certain purchasers elected
to receive pre-funded warrants (the &ldquo;Pre-Funded Warrants&rdquo;) at a purchase price of $5.1199 per Pre-Funded Warrant (equal to
the per Share purchase price less $0.0001). Each Pre-Funded Warrant is exercisable immediately upon issuance for one share of Common Stock
at an exercise price of $0.0001 per share and will remain exercisable until exercised in full. The shares of Common Stock issuable upon
exercise of the Pre-Funded Warrants are referred to herein as the &ldquo;Warrant Shares.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The issuance and sale
of the Shares and Pre-Funded Warrants was made in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities
Act and Rule 506(b) of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The May 2026 Private
Placement closed on May 11, 2026 (the &ldquo;Closing&rdquo;), and resulted in the issuance and sale of an aggregate of 85,202 Shares at
a purchase price of $5.12 per Share and 403,088 Pre-Funded Warrants at a purchase price of $5.1199 per Pre-Funded Warrant, for aggregate
gross proceeds of approximately $2.5 million, before deducting fees payable to the placement agent and other offering expenses payable
by the Company. The Company intends to use the net proceeds from the May 2026 Private Placement for working capital purposes, including
up to $900,000 in marketing expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
May 2026 Private Placement, the Company entered into a Placement Agent Agreement with E.F. Hutton &amp; Co. (&ldquo;E.F. Hutton&rdquo;),
pursuant to which E.F. Hutton acted as the exclusive placement agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the terms
of the Purchase Agreement, the aggregate number of shares of Common Stock issuable to the Investors in the May 2026 Private Placement
(including upon exercise of the Pre-Funded Warrants and giving effect to any anti-dilution and price adjustment provisions thereunder)
is subject to a cap of 19.99% of the Company&rsquo;s outstanding Common Stock immediately prior to the execution of the Purchase Agreement,
until such time as the Company obtains the approval of its stockholders required under applicable Nasdaq Listing Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
May 2026 Private Placement, the Company also entered into a Registration Rights Agreement with the Investors (the &ldquo;Registration
Rights Agreement&rdquo;), pursuant to which the Company agreed to provide certain registration rights with respect to the resale of the
Shares and the Warrant Shares, and agreed to file an initial registration statement within 30 days following the Closing to register the
resale of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On May 8, 2026, the Company
issued a press release announcing the pricing of the May 2026 Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sichenzia Ross Ference Carmel LLP served as counsel
to the Company in connection with the May 2026 Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus forms a part of the registration
statement that we are filing with the SEC to register the resale of the Shares and Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shares and Warrant Shares being offered by
the Selling Stockholders are those shares of common stock issued or issuable to the Selling Stockholders in the May 2026 Private Placement.
We are registering the Shares and Warrant Shares to permit the Selling Stockholders to offer such shares for resale from time to time.
Except for the ownership of the Shares and Pre-Funded Warrants, and the transactions contemplated pursuant to the Purchase Agreement,
none of the Selling Stockholders have had any material relationship with us within the past three (3) years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth certain information
with respect to each Selling Stockholder, including (i) the shares of common stock beneficially owned by each Selling Stockholder prior
to this offering, (ii) the number of shares being offered by each Selling Stockholder pursuant to this prospectus, and (iii) the Selling
Stockholders&rsquo; beneficial ownership after completion of this offering. The registration of the Shares and Warrant Shares issuable
to the Selling Stockholders does not necessarily mean that the Selling Stockholders will sell all or any of such shares, but the number
of shares of common stock and percentages set forth in the final two columns below assume that all shares of common stock being offered
by the Selling Stockholders are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table is based on information supplied to
us by the Selling Stockholders, with beneficial ownership and percentage ownership determined in accordance with the rules and regulations
of the SEC and includes voting or investment power with respect to shares of common stock. This information does not necessarily indicate
beneficial ownership for any other purpose. In computing the number of shares of common stock beneficially owned by each Selling Stockholder
and the percentage ownership of that Selling Stockholder, shares of common stock subject to Pre-Funded Warrants held by that Selling
Stockholder that are exercisable for shares of common stock within 60 days after May 29, 2026, are deemed outstanding. Such shares,
however, are not deemed outstanding for the purposes of computing the percentage ownership of any other stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of<BR>
    Shares of<BR>
    Common<BR>
    Stock<BR>
    Beneficially<BR>
    Owned<BR>
    Prior to<BR>
    Offering(1)</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum<BR>
    Number of<BR>
    Shares of<BR>
    Common<BR>
    Stock to be<BR>
    Sold<BR>
    Pursuant to<BR>
    this<BR>
    Prospectus(2)</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of<BR>
    Shares of<BR>
    Common<BR>
    Stock<BR>
    Beneficially<BR>
    Owned<BR>
    After<BR>
    Offering</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage<BR>
    Beneficially<BR>
    Owned<BR>
    After<BR>
    Offering</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 52%; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbo
    Capital Inc. (3)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">468,758</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">468,758</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARC
    Group International Ltd (4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,532</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,532</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">488,290</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">488,290</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Less than 1%</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1)</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents
shares of common stock and shares issuable upon exercise of Pre-Funded Warrants issued to the Selling Stockholders in the May 2026 Private
Placement and offered hereby.&nbsp;</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares beneficially owned and the percentage of beneficial ownership after this offering set forth in these columns are based on 1,437,157 shares of common stock outstanding as of May 29, 2026, which includes the 85,202 Shares issued to the Selling Stockholders in the May 2026 Private Placement, as of such date. These figures do not include 403,088 shares issuable upon exercise of the Pre-Funded Warrants. The calculation of beneficial ownership reported in such columns assumes the sale of all shares of common stock offered hereby by the Selling Stockholders.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of (i) 65,670 shares of common stock and (ii) 403,088 Pre-Funded
Warrants issuable in lieu thereof from the May 2026 Private Placement; in addition, this Selling Stockholder is deemed to hold 36,727,273
shares of common stock issuable upon conversion of the Series C Preferred Stock from the December 2025 Private Placement. Adam Chambers
holds voting and dispositive power over the securities reported herein held by Corbo Capital Inc. Mr. Chambers disclaims beneficial ownership
of the securities reported herein held by Corbo Capital Inc. The address of Corbo Capital Inc. is 405 5<SUP>th</SUP> Ave S, Naples, FL
34102.</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 19,532 shares of common stock issuable from the May 2026 Private Placement. Abraham Cinta is the Chief Executive Officer of ARC Group International Ltd and holds voting and dispositive power over the securities reported herein held by ARC Group International Ltd. Mr. Cinta disclaims beneficial ownership of the securities reported herein held by ARC Group International Ltd. The address of ARC Group International Ltd is 10 East 53<SUP>rd</SUP> Street, Suite 3001, New York, NY 10011.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_016"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Selling Stockholders and any of their respective
pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on any trading
market, stock exchange or other trading facility on which the securities are traded or in private transactions. These sales may be at
fixed or negotiated prices. The Selling Stockholders may use any one or more of the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary
                                            brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">block
                                            trades in which the broker-dealer will attempt to sell the securities as agent but may position
                                            and resell a portion of the block as principal to facilitate the transaction;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases
                                            by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an
                                            exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&Oslash;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">privately
                                            negotiated transactions;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&Oslash;<FONT STYLE="font-family: Wingdings; font-size: 10pt"></FONT></TD><TD STYLE="text-align: justify">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&Oslash;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in
                                            transactions through broker-dealers that agree with the Selling Stockholders to sell a specified
                                            number of such securities at a stipulated price per security;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">through
                                            the writing or settlement of options or other hedging transactions, whether through an options
                                            exchange or otherwise;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a
                                            combination of any such methods of sale; or</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any
                                            other method permitted pursuant to applicable law.</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Selling Stockholders may also sell securities
under Rule 144 under the Securities Act, if available, rather than under this prospectus.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broker-dealers engaged by the Selling Stockholders
may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders
(or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except
as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission
in compliance with FINRA Rule 2121.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sale of the securities
covered hereby, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may
also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers
that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers
or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other
financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may
resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders and any broker-dealers
or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities
Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale
of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. We are requesting
that each Selling Stockholder inform us that it does not have any written or oral agreement or understanding, directly or indirectly,
with any person to distribute the securities. The Company is required to pay certain fees and expenses incurred by the Company incident
to the registration of the shares. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages
and liabilities, including liabilities under the Securities Act.&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Because the Selling Stockholders may be deemed
to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, they will be subject to the prospectus delivery requirements
of the Securities Act, including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant
to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. We are requesting that each Selling
Stockholder confirm that there is no underwriter or coordinating broker acting in connection with the proposed sale of the resale securities
by the Selling Stockholder.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares will be sold only through registered
or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the shares may not
be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification
requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under applicable rules and regulations under the
Exchange Act, any person engaged in the distribution of the shares may not simultaneously engage in market making activities with respect
to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In
addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder,
including Regulation M, which may limit the timing of purchases and sales of shares of the Common Stock by the Selling Stockholders or
any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver
a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities
Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sichenzia Ross Ference Carmel LLP, New York,
New York, is acting as counsel in connection with the registration of our securities under the Securities Act, and as such, will pass
upon the validity of the securities offered in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of the Company, as of and for the years ended
December 31, 2025 and December 31, 2024 have been audited by Bush &amp; Associates CPA LLC (&ldquo;Bush &amp; Associates&rdquo;) as our
independent registered public accounting firm. Such financial statements are incorporated by reference in this prospectus in reliance
upon such reports, each given on the authority of such firms as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_001"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to incorporate by reference
information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available
documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we
are incorporating by reference future filings with the SEC, this prospectus will be updated and those future filings may modify or supersede
some of the information included or incorporated in this prospectus. You should read all information incorporated by reference to determine
whether any statement in this prospectus has been modified or superseded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus incorporates by reference the following documents
that we have filed with the SEC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                            Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026038607/ea0283252-10k_ispecimen.htm">Form 10-K</A> for the fiscal year ended December 31, 2025, filed with the SEC on April 1, 2026;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>our Quarterly Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026058050/ea0290580-10q_ispecimen.htm">Form 10-Q</A> for the quarter ended March 31, 2026,
, filed with the SEC on May 18,
2026;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026000496/ea0271422-8k_ispecimen.htm">January 2, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026001257/ea0271900-8k_ispecimen.htm">January 5, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026005138/ea0273091-8ka1_ispecimen.htm">January 16, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026008215/ea0274218-8k_ispecimen.htm">January 27, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026013265/ea0275230-8k_ispecimen.htm">February 6, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026017963/ea0277498-8k_ispecimen.htm">February 18, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026019354/ea0277937-8k_ispecimen.htm">February 23, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026027736/ea0281614-8k_ispecimen.htm">March 13, 2026</A>, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026042468/ea0285909-8k_ispecimen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 10, 2026</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026042976/ea0285981-8k_ispecimen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 13, 2026</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026051013/ea0288258-8k_ispecimen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 1, 2026</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 13, 2026</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(other than information furnished pursuant to Item 2.02 or Item 7.01 of any Current Report on Form 8-K and any exhibits filed on such form that are related to such items, unless otherwise specifically stated in such Current Report or in this prospectus); and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of securities contained in our annual report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1558569/000155837022004077/ispc-20211231x10k.htm">Form 10-K</A> filed on March 22, 2022, including any amendment or report filed for the purpose of updating such description.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, all reports and other documents
that we file under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the effectiveness of the registration statement of which
this prospectus forms a part and prior to the termination of this offering shall be deemed to be incorporated by reference into this
prospectus and will automatically update and supersede the information contained or incorporated in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You may request a complimentary copy of any of the
documents incorporated by reference in this prospectus (other than exhibits, unless they are specifically incorporated by reference in
such documents) by writing or telephoning us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Katharyn Field</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">8 Cabot Road, Suite 1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Woburn, MA 01801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(781) 301-6700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibits to the filings will not be sent, however,
unless those exhibits have specifically been incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The documents incorporated by reference may be accessed
at our website: ispecimen.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_019"></A>WHERE YOU CAN FIND ADDITIONAL
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You can read our SEC filings, including the registration
statement, over the internet at the SEC&rsquo;s website at www.sec.gov. We are subject to the information reporting
requirements of the Exchange Act, and we file reports, proxy statements and other information with the SEC, which are available on the
SEC&rsquo;s website referred to above. We also maintain a website at www.iSpecimen.com, at which you
may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to,
the SEC. However, the information contained in or accessible through our website is not part of this prospectus or the registration statement
of which this prospectus forms a part, and investors should not rely on such information in making a decision to purchase our common stock
in this offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029163701_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>iSpecimen Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>488,290 Shares of Common Stock</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the expenses in connection with this
registration statement. All of such expenses are estimates, other than the filing fees payable to the Securities and Exchange Commission
and to FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount<BR> to be<BR> Paid</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Filing Fee - Securities and Exchange Commission</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">216.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer agent&rsquo;s and registrar fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Printing fees and expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6716.80</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 145 of the Delaware General Corporation
Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including
attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection
with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person
being or having been a director, officer, employee or agent of the corporation. Section 145 of the Delaware General Corporation Law also
provides that expenses (including attorneys&rsquo; fees) incurred by a director or officer in defending an action may be paid by a corporation
in advance of the final disposition of an action if the director or officer undertakes to repay the advanced amounts if it is determined
such person is not entitled to be indemnified by the corporation. The Delaware General Corporation Law provides that Section 145 is not
exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or
disinterested directors or otherwise. Our third amended and restated bylaws provide that, to the fullest extent permitted by law, we
shall indemnify and hold harmless any person who was or is made or is threatened to be made a party or is otherwise involved in any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that
such person, or the person for whom he is the legally representative, is or was a director or officer of ours, against all liabilities,
losses, expenses (including attorney&rsquo;s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
by such person in connection with such proceeding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 102(b)(7) of the Delaware General Corporation
Law permits a corporation to provide in its Certificate of Incorporation that a director of the corporation shall not be personally liable
to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for
any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith
or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments of dividends or unlawful stock repurchases,
redemptions or other distributions, or (iv) for any transaction from which the director derived an improper personal benefit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our fifth amended and restated certificate of
incorporation provides that we shall, to the maximum extent permitted from time to time under the law of the State of Delaware, indemnify
and upon request shall advance expenses to any person who is or was a party or is threatened to be made a party to any threatened, pending
or completed action, suit, proceeding or claim, whether civil, criminal, administrative or investigative, by reason of the fact that
such person is or was or has agreed to be a director or officer of ours or while a director or officer is or was serving at our request
as a director, officer, partner, trustee, employee or agent of any corporation, partnership, joint venture, trust or other enterprise,
including service with respect to employee benefit plans, against expenses (including attorneys&rsquo; fees and expenses), judgments,
fines, penalties and amounts paid in settlement incurred in connection with the investigation, preparation to defend or defense of such
action, suit, proceeding or claim; provided, however, that the foregoing shall not require us to indemnify or advance expenses to any
person in connection with any action, suit, proceeding or claim initiated by or on behalf of such person or any counterclaim against
us initiated by or on behalf of such person. Such indemnification shall not be exclusive of other indemnification rights arising under
any by-law, agreement, vote of directors or stockholders or otherwise and shall inure to the benefit of the heirs and legal representatives
of such person. Any person seeking indemnification shall be deemed to have met the standard of conduct required for such indemnification
unless the contrary shall be established. Any repeal or modification of our fifth amended and restated certificate of incorporation
shall not adversely affect any right or protection of a director or officer of ours with respect to any acts or omissions of such director
or officer occurring prior to such repeal or modification.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our fifth amended and restated certificate of
incorporation and third amended and restated bylaws provide we shall, to the fullest extent permitted under the laws of the State of
Delaware, as amended and supplemented from time to time, indemnify each person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason
of the fact that such party is or was, or has agreed to become, a director or officer of ours, or is or was serving, or has agreed to
serve, at our request, as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture,
trust or other enterprise, including any employee benefit plan, or by reason of any action alleged to have been taken or omitted in such
capacity, against all expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by such party or on such party&rsquo;s behalf in connection with such action, suit or proceeding and any appeal therefrom.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Expenses incurred by such a person in defending
a civil or criminal action, suit or proceeding by reason of the fact that such person is or was, or has agreed to become, a director
or officer of ours, or is or was serving, or has agreed to serve, at our request, as a director, officer or trustee of, or in a similar
capacity with, another corporation, partnership, joint venture, trust or other enterprise, including any employee benefit plan, or by
reason of any action alleged to have been taken or omitted in such capacity shall be paid by us in advance of the final disposition of
such action, suit or proceeding upon receipt of an undertaking by or on behalf of such person to repay such amount if it shall ultimately
be determined that he is not entitled to be indemnified by us as authorized by relevant sections of the Delaware General Corporation
Law. Notwithstanding the foregoing, we shall not be required to advance such expenses to a person who is a party to an action, suit or
proceeding brought by us and approved by a majority of our Board of Directors that alleges willful misappropriation of corporate assets
by such person, disclosure of confidential information in violation of such person&rsquo;s fiduciary or contractual obligations to us
or any other willful and deliberate breach in bad faith of such person&rsquo;s duty to us or our stockholders.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We shall not indemnify any such person seeking
indemnification in connection with a proceeding (or part thereof) initiated by such person unless the initiation thereof was approved
by our Board of Directors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The indemnification rights provided in our fifth
amended and restated certificate of incorporation and third amended and restated bylaws shall not be deemed exclusive of any other rights
to which those indemnified may be entitled under any by-law, agreement or vote of stockholders or disinterested directors or otherwise,
both as to action in their official capacities and as to action in another capacity while holding such office, continue as to such person
who has ceased to be a director or officer, and inure to the benefit of the heirs, executors and administrators of such a person.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the Delaware General Corporation Law is amended
to expand further the indemnification permitted to indemnitees, then we shall indemnify such persons to the fullest extent permitted
by the Delaware General Corporation Law, as so amended.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may, to the extent authorized from time to
time by our Board of Directors, grant indemnification rights to other employees or agents of ours or other persons serving us and such
rights may be equivalent to, or greater or less than, those set forth in our third amended and restated bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our obligation to provide indemnification under
our third amended and restated bylaws shall be offset to the extent of any other source of indemnification or any otherwise applicable
insurance coverage under a policy maintained by us or any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To assure indemnification under our third amended
and restated bylaws of all directors, officers, employees or agents who are determined by us or otherwise to be or to have been &ldquo;fiduciaries&rdquo;
of any employee benefit plan of ours that may exist from time to time, Section 145 of the Delaware General Corporation Law shall, for
the purposes of our third amended and restated bylaws, be interpreted as follows: an &ldquo;other enterprise&rdquo; shall be deemed to
include such an employee benefit plan, including without limitation, any plan of ours that is governed by the Act of Congress entitled
&ldquo;Employee Retirement Income Security Act of 1974,&rdquo; as amended from time to time; we shall be deemed to have requested a person
to serve an employee benefit plan where the performance by such person of his duties to us also imposes duties on, or otherwise involves
services by, such person to the plan or participants or beneficiaries of the plan; and excise taxes assessed on a person with respect
to an employee benefit plan pursuant to such Act of Congress shall be deemed &ldquo;fines.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Our third amended and restated bylaws shall be
deemed to be a contract between us and each person who was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that person
is or was, or has agreed to become, a director or officer of ours, or is or was serving, or has agreed to serve, at our request, as a
director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise,
including any employee benefit plan, or by reason of any action alleged to have been taken or omitted in such capacity, at any time while
this bylaw is in effect, and any repeal or modification thereof shall not affect any rights or obligations then existing with respect
to any state of facts then or theretofore existing or any action, suit or proceeding theretofore or thereafter brought based in whole
or in part upon any such state of facts.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The indemnification provision of our third amended
and restated bylaws does not affect directors&rsquo; responsibilities under any other laws, such as the federal securities laws or state
or federal environmental laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may purchase and maintain insurance on behalf
of any person who is or was a director, officer or employee of ours, or is or was serving at our request as a director, officer, employee
or agent of another company, partnership, joint venture, trust or other enterprise against liability asserted against him and incurred
by him in any such capacity, or arising out of his status as such, whether or not we would have the power to indemnify him against liability
under the provisions of this section. We currently maintain such insurance. The right of any person to be indemnified is subject to our
right, in lieu of such indemnity, to settle any such claim, action, suit or proceeding at our expense of by the payment of the amount
of such settlement and the costs and expenses incurred in connection therewith.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling our Company pursuant to the foregoing provisions,
or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that a claim for indemnification
against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered herewith, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit
to the court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 15. Recent Sales of Unregistered Securities.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On May 8, 2026, we entered
into the Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell 488,281 shares of
its common stock, par value $0.0001 per share, at a purchase price of $5.12 per share, and pre-funded warrants to purchase up to 403,088
shares of common stock at a purchase price of $5.1199 per pre-funded warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The May 2026 Private
Placement closed on May 11, 2026, and resulted in the issuance and sale of an aggregate of 85,202 Shares and 403,088 Pre-Funded Warrants
for aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees and other offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The sale and the issuance of the foregoing securities
were offered and sold in reliance upon exemptions from registration pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of
Regulation D promulgated under the Securities Act (&ldquo;Regulation D&rdquo;). We made this determination based on the representations
of each investor which included, in pertinent part, that each such investor was either (a) an &ldquo;accredited investor&rdquo; within
the meaning of Rule 501 of Regulation D or (b) a &ldquo;qualified institutional buyer&rdquo; within the meaning of Rule 144A under the
Securities Act and upon such further representations from each investor that (i) such investor acquired the securities for his, her or
its own account for investment and not for the account of any other person and not with a view to or for distribution, assignment or
resale in connection with any distribution within the meaning of the Securities Act, (ii) such investor agreed not to sell or otherwise
transfer the purchased securities unless they are registered under the Securities Act and any applicable state securities laws, or an
exemption or exemptions from such registration are available, (iii) such investor had knowledge and experience in financial and business
matters such that he, she or it was capable of evaluating the merits and risks of an investment in us, (iv) such investor had access
to all of our documents, records, and books pertaining to the investment and was provided the opportunity to ask questions and receive
answers regarding the terms and conditions of the offering and to obtain any additional information which we possessed or were able to
acquire without unreasonable effort and expense, and (v) such investor had no need for the liquidity in its investment in us and could
afford the complete loss of such investment. In addition, there was no general solicitation or advertising for securities issued in reliance
upon these exemptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of Exhibit</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000121390026051013/ea028825801ex3-1.htm">Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K filed with the SEC on May 1, 2026).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921084200/tm2120278d1_ex3-2.htm">Second
    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Company&rsquo;s Form 8-K filed with the SEC on June
    22, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000121390025062804/ea024839601ex3-1_ispecimen.htm">Third
    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K filed with the SEC on July
    10, 2025).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921144133/tm2134042d1_ex4-1.htm">Form
    of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Form 8-K filed with the SEC on
    November 29, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921105435/tm2125103d1_ex10-2.htm">Warrant
    to Purchase Stock &ndash; Western Alliance Bank (incorporated by reference as Exhibit 10.2 to the Company&rsquo;s Form 8-K filed
    with the SEC on August 16, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000155837022004077/ispc-20211231xex4d3.htm">Description
    of Securities (incorporated by reference to Exhibit 4.3 of the Company&rsquo;s Form 10-K filed with the SEC on March 22, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465924102855/tm2424693d1_ex4-1.htm">Senior
    Note, dated as of September 25, 2024 (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Form 8-K filed with the SEC
    on September 25, 2024)</A>.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465924113112/tm2427232d1_ex4-1.htm">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Form 8-K filed with the SEC on October 31,
    2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000121390025039321/ea022875801ex4-5_ispecimen.htm">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-1, as amended (File No. 333-286958)).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000121390025072070/ea025123402ex4-1_ispecimen.htm">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Form 8-K filed with the SEC on August 5, 2025).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">4.8</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea029014301ex4-1.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Form 8-K filed with the SEC on May 13, 2026).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea0291637ex5-1.htm">Legal Opinion of Sichenzia Ross Ference Carmel LLP</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921105435/tm2125103d1_ex10-1.htm">Loan
    and Security Agreement (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed with the SEC on August 16,
    2021)</A>.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921105435/tm2125103d1_ex10-2.htm">Warrant
    to Purchase Common Stock issued to Western Alliance Bank on August 13, 2021 (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s
    Form 8-K filed with the SEC on August 16, 2021)</A>.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921144133/tm2134042d1_ex10-1.htm">Securities
    Purchase Agreement, dated November 28, 2021, by and between the Company and the purchasers named therein (incorporated by reference
    to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed with the SEC on November 29, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921144133/tm2134042d1_ex10-2.htm">Registration
    Rights Agreement, dated November 28, 2021, by and between the Company and the investors named therein (incorporated by reference
    to Exhibit 10.2 of the Company&rsquo;s Form 8-K filed with the SEC on November 29, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921144133/tm2134042d1_ex10-3.htm">Placement
    Agency Agreement, dated November 28, 2021, by and between the Company and ThinkEquity LLC (incorporated by reference to Exhibit 10.3
    of the Company&rsquo;s Form 8-K filed with the SEC on November 29, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-1.htm">iSpecimen
    Inc. 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form S-1/A (File No. 333-250198)
    with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-2.htm">iSpecimen
    Inc. 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Form S-1/A (File No. 333-250198)
    with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-3.htm">Form
    of Indemnification Agreement, by and between the Company and certain directors and executive officers (incorporated by reference
    to Exhibit 10.3 of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-4.htm">Form
    of Confidentiality, Non-Competition And Assignment Agreement, by and between iSpecimen Inc. and each of its employees (incorporated
    by reference to Exhibit 10.4 of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-5.htm">Lease
    between the Company and Bedford Street LLC (incorporated by reference to Exhibit 10.5 of the Company&rsquo;s Form S-1/A (File No.
    333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-6.htm">Form
    of Series A Preferred Stock Subscription Agreement (incorporated by reference to Exhibit 10.6 of the Company&rsquo;s Form S-1/A (File
    No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-7.htm">Capital
    Commitment Agreement, dated September 1, 2012 (incorporated by reference to Exhibit 10.7 of the Company&rsquo;s Form S-1/A (File
    No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-8.htm">Form
    of Series B Preferred Stock Purchase Agreement, dated August 22, 2014 (incorporated by reference to Exhibit 10.8 of the Company&rsquo;s
    Form S-1/A (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-9.htm">Form
    of Investors&rsquo; Rights Agreement for Series A-1 Preferred Stock and Series B Preferred Stock Investors (incorporated by reference
    to Exhibit 10.9 of the Company&rsquo;s Form S-1/A (File No. 333- 250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-10.htm">Form
    of Convertible Note Subscription Agreement (incorporated by reference to Exhibit 10.10 of the Company&rsquo;s Form S-1/A (File No.
    333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-11.htm">Form
    of Unsecured Convertible Promissory Note (incorporated by reference to Exhibit 10.11 of the Company&rsquo;s Form S-1/A (File No.
    333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-12.htm">Unsecured
    Convertible Promissory Note, dated December 29, 2017, issued by the Company to Anna- Maria and Stephen Kellen Foundation, Inc. (incorporated
    by reference to Exhibit 10.12 of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109.9pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109.9pt; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109.9pt; text-align: center; background-color: white">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-13.htm">Omnibus
    Amendment to Unsecured Convertible Notes and Subscription Agreement, dated August 3, 2018, by and among the Company, Andrew L. Ross,
    Anna-Maria and Stephen Kellen Foundation, Inc., and OBF Investments, LLC (incorporated by reference to Exhibit 10.13 of the Company&rsquo;s
    Form S-1/A &nbsp;(File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-14.htm">Second
    Omnibus Amendment to Unsecured Convertible Notes and Subscription Agreement, dated May 1, 2019, by and among iSpecimen Inc., Andrew
    L. Ross, Anna-Maria and Stephen Kellen Foundation, Inc., and OBF Investments, LLC (incorporated by reference to Exhibit 10.14 of
    the Company&rsquo;s Form S- 1/A (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-15.htm">Third
    Omnibus Amendment to Unsecured Convertible Notes and Subscription Agreement, dated November 15, 2019, by and among iSpecimen Inc.,
    Andrew L. Ross, Anna-Maria and Stephen Kellen Foundation, Inc., and OBF Investments, LLC (incorporated by reference to Exhibit 10.15
    of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-16.htm">Fourth
    Omnibus Amendment to Unsecured Convertible Notes and Subscription Agreement, dated September 19, 2020, by and among iSpecimen Inc.,
    Andrew L. Ross, Anna-Maria and Stephen Kellen Foundation, Inc., and OBF Investments, LLC (incorporated by reference to Exhibit 10.16
    of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-17.htm">Form
    of Note Subscription Agreement for Secured Bridge Debt (incorporated by reference to Exhibit 10.17 of the Company&rsquo;s Form S-1/A
    (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-18.htm">Form
    of Secured Promissory Note for Secured Bridge Debt (incorporated by reference to Exhibit 10.18 of the Company&rsquo;s Form S-1/A
    (File No. 333-250198) with the SEC on December 31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-19.htm">First
    Amendment to Note Subscription Agreements and Secured Promissory Notes, dated May 1, 2019, by and among the Company and Note Investors
    (incorporated by reference to Exhibit 10.19 of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December 31,
    2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-20.htm">Second
    Amendment to Note Subscription Agreements and Secured Promissory Notes, dated November 15, 2019, by and among the Company and Note
    Investors (incorporated by reference to Exhibit 10.20 of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December
    31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-21.htm">Third
    Amendment to Note Subscription Agreements and Secured Promissory Notes, dated June 15, 2020, by and among the Company and Note Investors
    (incorporated by reference to Exhibit 10.21 of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December 31,
    2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465920141041/tm2035427d4_ex10-22.htm">Fourth
    Amendment to Note Subscription Agreements and Secured Promissory Notes, dated October 1, 2020, by and among the Company and Note
    Investors (incorporated by reference to Exhibit 10.22 of the Company&rsquo;s Form S-1/A (File No. 333-250198) with the SEC on December
    31, 2020).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921046101/tm2035427d11_ex10-23.htm">Fifth
    Amendment to Note Subscription Agreements and Secured Promissory Notes, dated March 15, 2021, by and among the Company and Note Investors
    (incorporated by reference to Exhibit 10.23 of the Company&rsquo;s Form S-1/A3 (File No. 333-250198) with the SEC on April 2, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922065199/tm2217039d1_ex10-1.htm">iSpecimen
    Inc. Second Amended and Restated 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form
    8-K filed with the SEC on May 26, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921046101/tm2035427d11_ex10-25.htm">Executive
    Employment Agreement by and between the Company and Christopher lanelli (incorporated by reference to Exhibit 10.25 of the Company&rsquo;s
    Form S-1/A3 (File No. 333-250198) with the SEC on April 2, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921046101/tm2035427d11_ex10-26.htm">Executive
    Employment Agreement by and between the Company and Jill Mullan (incorporated by reference to Exhibit 10.26 of the Company&rsquo;s
    Form S-1/A3 (File No. 333-250198) with the SEC on April 2, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921046101/tm2035427d11_ex10-27.htm">Executive
    Employment Agreement by and between the Company and Tracy Curley (incorporated by reference to Exhibit 10.27 of the Company&rsquo;s
    Form S-1/A3 (File No. 333-250198) with the SEC on April 2, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921046101/tm2035427d11_ex10-28.htm">Employment
    Agreement by and between the Company and Benjamin Bielak (incorporated by reference to Exhibit 10.28 of the Company&rsquo;s Form
    S-1/A3 (File No. 333-250198) with the SEC on April 2, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921055687/tm2035427d14_ex10-29.htm">Factoring
    Agreement, dated January 1, 2021, by and between iSpecimen Inc. and Versant Funding, LLC &nbsp;(incorporated by reference to Exhibit
    10.29 of the Company&rsquo;s Form S-1/A4 (File No. 333-250198) filed with the SEC on April 27, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922053841/tm2213955d1_ex10-1.htm">Waiver
    Agreement, dated April 29, 2022, by and between the Company and Western Alliance Bank &nbsp;(incorporated by reference to Exhibit
    10.1 of the Company&rsquo;s Form 8-K filed with the SEC on April 29, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922072733/tm2218906d1_ex10-1.htm">First
    Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Christopher Ianelli (incorporated
    by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K&nbsp;filed with the SEC on June 21, 2022).</A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37#</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922072733/tm2218906d1_ex10-2.htm">First
    Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Jill Mullan (incorporated by reference
    to Exhibit 10.2 of the Company&rsquo;s Form 8-K filed with the SEC on June 21, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922072733/tm2218906d1_ex10-3.htm">First
    Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Tracy Curley (incorporated by reference
    to Exhibit 10.3 of the Company&rsquo;s Form 8-K filed with the SEC on June 21, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922072733/tm2218906d1_ex10-4.htm">First
    Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Benjamin Bielak (incorporated by
    reference to Exhibit 10.4 of the Company&rsquo;s Form 8-K filed with the SEC on June 21, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40+#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922112436/tm2229013d1_ex10-1.htm">First
    Amended and Restated Executive Employment Agreement, dated October 24, 2022, by and between Tracy Wilson Curley and iSpecimen Inc.
    (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed with the SEC on October 28, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922112436/tm2229013d1_ex10-2.htm">First
    Restated Noncompetition, Nonsolicitation, Nondisclosure and Inventions Agreement, dated October 24, 2022, by and between Tracy Wilson
    Curley and iSpecimen Inc. (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Form 8-K filed with the SEC on October
    28, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42+#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922112436/tm2229013d1_ex10-3.htm">First
    Amended and Restated Executive Employment Agreement, dated October 24, 2022, by and between Benjamin Bielak and iSpecimen Inc. (incorporated
    by reference to Exhibit 10.3 of the Company&rsquo;s Form 8-K filed with the SEC on October 28, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922112436/tm2229013d1_ex10-4.htm">First
    Restated Noncompetition, Nonsolicitation, Nondisclosure and Inventions Agreement, dated October 24, 2022, by and between Benjamin
    Bielak and iSpecimen Inc. (incorporated by reference to Exhibit 10.4 of the Company&rsquo;s Form 8-K filed with the SEC on October
    28, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44+</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922112436/tm2229013d1_ex10-5.htm">Separation
    Agreement, dated October 24, 2022, by and between Christopher Ianelli and iSpecimen Inc. (incorporated by reference to Exhibit 10.5
    of the Company&rsquo;s Form 8-K filed with the SEC on October 28, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45+</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465922112436/tm2229013d1_ex10-6.htm">Separation
    Agreement effective October 24, 2022, by and between Jill Mullan and iSpecimen Inc. (incorporated by reference to Exhibit 10.6 of
    the Company&rsquo;s Form 8-K filed with the SEC on October 28, 2022).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465924102855/tm2424693d1_ex10-1.htm">Note
    Purchase Agreement, dated as of September 19, 2024 (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed
    with the SEC on September 25, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465924113112/tm2427232d1_ex10-1.htm">Form
    of Placement Agency Agreement, dated as of October 29, 2024 (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form
    8-K filed with the SEC on October 31, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465924113112/tm2427232d1_ex10-2.htm">Form
    of Securities Purchase Agreement, dated as of October 29, 2024 (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s
    Form 8-K filed with the SEC on October 31, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465924113112/tm2427232d1_ex10-3.htm">Investor
    Relations Agreement, dated October 31, 2024, by and between the Company and IR Agency LLC (incorporated by reference to Exhibit 10.3
    of the Company&rsquo;s Form 8-K filed with the SEC on October 31, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000121390025039321/ea022875801ex1-1_ispecimen.htm">Form
    of Underwriting Agreement (incorporated by reference to Exhibit 1.1 to the Registration Statement on Form S-1, as amended (File No.
    333-286958)).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000121390025053464/ea024521201ex10-45_ispecimen.htm">Consulting Agreement with IR Agency LLC (incorporated by reference to Exhibit 10.45 to the Registration Statement on Form S-1, as amended (File No. 333-286958)).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000121390025053464/ea024521201ex10-46_ispecimen.htm">Software Purchase and Services Agreement with Sales Stack Solutions Corp. (incorporated by reference to Exhibit 10.46 to the Registration Statement on Form S-1, as amended (File No. 333-286958)).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001558569/000121390025072070/ea025123402ex10-1_ispecimen.htm">Form
    of&nbsp;Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed with the SEC
    on August 5, 2025).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001558569/000121390025072070/ea025123402ex10-2_ispecimen.htm">Form
    of&nbsp;Registration Rights Agreement (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Form 8-K filed with the SEC
    on August 5, 2025).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/0001558569/000121390025072070/ea025123402ex10-3_ispecimen.htm">Investor
    Relations Agreement by and between the Company and IR Agency LLC (incorporated by reference to Exhibit 10.3 of the Company&rsquo;s
    Form 8-K filed with the SEC on August 5, 2025).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1558569/000110465921055687/tm2035427d14_ex14.htm">Form
    of Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14 of the Company&rsquo;s Form S-1/A4 (File No. 333-250198)
    filed with the SEC on April 27, 2021).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea029163701ex23-1.htm">Consent of Bush &amp; Associates CPA LLC.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea0291637ex5-1.htm">Consent of Sichenzia Ross Ference Carmel LLP (contained in Exhibit 5.1).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1558569/000155837024003129/ispc-20231231xex97d1.htm">iSpecimen
    Inc. Executive Compensation Clawback Policy (Adopted on October 27, 2023) (incorporated by reference to Exhibit 97.1 of the Company&rsquo;s
    Form 10-K filed with the SEC on March 13, 2024).</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea0291637ex-fee.htm">Filing Fee Table</A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed
                                            herewith.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">**</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Furnished
                                            herewith.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">+</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Schedules
                                            and exhibits have been omitted pursuant to Items 601(a)(5) and 601(b)(2) of Regulation S-K.
                                            The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to
                                            the SEC upon request.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">#</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Indicates
                                            management contract or compensatory plan or arrangement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To
                                            file, during any period in which offers or sales are being made, a post-effective amendment
                                            to this registration statement:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To
                                            include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To
                                            reflect in the prospectus any facts or events arising after the effective date of this registration
                                            statement (or the most recent post-effective amendment thereof) which, individually or in
                                            the aggregate, represent a fundamental change in the information set forth in this registration
                                            statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities
                                            offered (if the total dollar value of the securities offered would not exceed that which
                                            was registered) and any deviation from the low or high end of the estimated maximum offering
                                            range may be reflected in the form of prospectus filed with the Securities and Exchange Commission
                                            pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
                                            more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation
                                            of Registration Fee&rdquo; table in the effective registration statement; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To
                                            include any material information with respect to the plan of distribution not previously
                                            disclosed in this registration statement or any material change to such information in this
                                            registration statement;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provided, however, that the undertakings set
forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, that are incorporated by reference in this registration
statement or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That,
                                            for the purpose of determining any liability under the Securities Act of 1933, as amended,
                                            each such post-effective amendment shall be deemed to be a new registration statement relating
                                            to the securities offered therein, and the offering of such securities at that time shall
                                            be deemed to be the initial bona fide offering thereof;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To
                                            remove from registration by means of a post-effective amendment any of the securities being
                                            registered which remain unsold at the termination of the offering;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That,
                                            for the purpose of determining liability under the Securities Act of 1933, as amended, to
                                            any purchaser:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each
                                            prospectus filed by the registrant pursuant to Rule 424 (b)(3) shall be deemed to be part
                                            of this registration statement as of the date the filed prospectus was deemed part of and
                                            included in this registration statement; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each
                                            prospectus required to be filed pursuant to Rule 424 (b)(2), (b)(5), or (b)(7) as part of
                                            a registration statement in reliance on Rule 430B relating to an offering made pursuant to
                                            Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by
                                            Section 10(a) of the Securities Act of 1933, as amended, shall be deemed to be part of and
                                            included in the registration statement as of the earlier of the date such prospectus is first
                                            used after effectiveness or the date of the first contract of sale of securities in the offering
                                            described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer
                                            and any person that is at that date an underwriter, such date shall be deemed to be a new
                                            effective date of the registration statement relating to the securities in the registration
                                            statement to which that prospectus relates, and the offering of such securities at that time
                                            shall be deemed to be the initial bona fide offering thereof; provided, however, that no
                                            statement made in a registration statement or prospectus that is part of the registration
                                            statement or made in a document incorporated or deemed incorporated by reference into the
                                            registration statement or prospectus that is part of the registration statement will, as
                                            to a purchaser with a time of contract of sale prior to such effective date, supersede or
                                            modify any statement that was made in the registration statement or prospectus that was part
                                            of the registration statement or made in any such document immediately prior to such effective
                                            date;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That,
                                            for the purpose of determining liability of the registrant under the Securities Act of 1933,
                                            as amended, to any purchaser in the initial distribution of the securities, the undersigned
                                            registrant undertakes that in a primary offering of securities of the undersigned registrant
                                            pursuant to this registration statement, regardless of the underwriting method used to sell
                                            the securities to the purchaser, if the securities are offered or sold to such purchaser
                                            by means of any of the following communications, the undersigned registrant will be a seller
                                            to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                            preliminary prospectus or prospectus of the undersigned registrant relating to the offering
                                            required to be filed pursuant to Rule 424;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                            free writing prospectus relating to the offering prepared by or on behalf of the undersigned
                                            registrant or used or referred to by the undersigned registrant;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            portion of any other free writing prospectus relating to the offering containing material
                                            information about the undersigned registrant or its securities provided by or on behalf of
                                            the undersigned registrant; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                            other communication that is an offer in the offering made by the undersigned registrant to
                                            the purchaser;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That,
                                            for purposes of determining any liability under the Securities Act of 1933, as amended, each
                                            filing of the registrant&rsquo;s annual report pursuant to Section 13(a) or Section 15(d)
                                            of the Securities Exchange Act of 1934, as amended (and, where applicable, each filing of
                                            an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Securities
                                            Exchange Act of 1934, as amended) that is incorporated by reference in the registration statement
                                            shall be deemed to be a new registration statement relating to the securities offered therein,
                                            and the offering of such securities at that time shall be deemed to be the initial bona fide
                                            offering thereof;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Insofar
                                            as indemnification for liabilities arising under the Securities Act of 1933, as amended,
                                            may be permitted to directors, officers and controlling persons of the registrant pursuant
                                            to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
                                            of the Securities and Exchange Commission such indemnification is against public policy as
                                            expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In
                                            the event that a claim for indemnification against such liabilities (other than the payment
                                            by the registrant of expenses incurred or paid by a director, officer or controlling person
                                            of the registrant in the successful defense of any action, suit or proceeding) is asserted
                                            by such director, officer or controlling person in connection with the securities being registered,
                                            the registrant will, unless in the opinion of its counsel the matter has been settled by
                                            controlling precedent, submit to a court of appropriate jurisdiction the question whether
                                            such indemnification by it is against public policy as expressed in the Securities Act of
                                            1933, as amended, and will be governed by the final adjudication of such issue.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Act of 1933, as amended,
the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in
Woburn, State of Massachusetts, on the 4th day of June 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>iSPECIMEN INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Katharyn
                                            Field</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Katharyn Field&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KNOW ALL MEN BY THESE PRESENTS, that each person
whose individual signature appears below hereby authorizes and appoints Katharyn Field and Yuying Liang and each of them, with full power
of substitution and resubstitution and full power to act without the other, as his true and lawful attorney-in-fact and agent to act
in his or her name, place and stead, and to execute in the name and on behalf of each person, individually and in each capacity stated
below, and to file any and all amendments to this registration statement, any related registration statement filed pursuant to Rule 462(b)
under the Securities Act of 1933, as amended, and any or all pre- or post-effective amendments thereto, and to file the same, with all
exhibits thereto, and all other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and
necessary to be done in and about the premises, as fully for all intents and purposes as he or she might or could do in person, hereby
ratifying and confirming that said attorneys-in-fact and agents, and each of them, or any substitute or substitutes for each of them,
may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Pursuant to the requirements of the Securities
Act of 1933, as amended, this registration statement on Form S-3 has been signed by the following persons in the capacities set forth
opposite their names.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 22%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Katharyn Field</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Treasurer,</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 4, 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Katharyn Field</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Secretary </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yuying Liang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting and Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 4, 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuying Liang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Anthony Lau</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 4, 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony Lau</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Avtar Dhaliwal</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 4, 2026&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avtar Dhaliwal</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Arphing (Tommy) Lee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 4, 2026</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arphing (Tommy) Lee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 167.8pt 0pt 168.65pt; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea0291637ex5-1.htm
<DESCRIPTION>LEGAL OPINION OF SICHENZIA ROSS FERENCE CARMEL LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><IMG SRC="ea029163701_ex5-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 4, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">iSpecimen Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8 Cabot Road, Suite 1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Woburn, MA 08101</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Re: iSpecimen Inc. - Registration Statement
on Form S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is furnished to you in connection
with a Registration Statement on Form S-3 (the &ldquo;<B>Registration Statement</B>&rdquo;) filed with the Securities and Exchange Commission
(the &ldquo;<B>Commission</B>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), for the
registration of the resale of up to an aggregate of 488,290 shares of common stock, par value $0.0001 per share (the &ldquo;<B>Common
Stock</B>&rdquo;), of iSpecimen Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), consisting of (i) up to 85,202 shares
of Common Stock (the &ldquo;<B>Shares</B>&rdquo;) issued in connection with the May 2026 Private Placement (as defined below), and (ii)
up to 403,088 shares of Common Stock (the &ldquo;<B>Warrant Shares</B>&rdquo;) issuable upon exercise of pre-funded warrants (the &ldquo;<B>Pre-Funded
Warrants</B>&rdquo;) issued in connection with the May 2026 Private Placement, all of which were issued by the Company in connection with
a private placement transaction completed on May 11, 2026 (the &ldquo;<B>May 2026 Private Placement</B>&rdquo;) pursuant to a securities
purchase agreement, dated as of May 8, 2026 (the &ldquo;<B>Purchase Agreement</B>&rdquo;). The Shares and Warrant Shares are being registered
on behalf of the selling stockholders named in the Registration Statement (the &ldquo;<B>Selling Stockholders</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As counsel to the Company, we have examined
the Registration Statement and the originals or copies, certified or otherwise identified to our satisfaction, of such other documents,
corporate records, certificates of public officials and other instruments as we have deemed necessary for the purposes of rendering this
opinion and we are familiar with the proceedings taken and proposed to be taken by the Company in connection with the filing of the Registration
Statement as it relates to the Shares and the Warrant Shares. In our examination, we have assumed the genuineness of all signatures, the
authenticity of all documents submitted to us as originals and the conformity with the originals of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have assumed that,
at or prior to the time of the delivery of any of the Shares or Warrant Shares, there will not have occurred any change in the law or
the facts affecting the validity of the Shares or Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject
to the foregoing, we are of the opinion that (i) the Shares have been duly authorized and are validly issued, fully paid and nonassessable,
and (ii) the Warrant Shares have been duly authorized and reserved for issuance and, when issued upon exercise of the Pre-Funded Warrants
in accordance with their terms, will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinions expressed herein are limited
solely to the General Corporation Law of the State of Delaware, including the applicable provisions of the Delaware Constitution and the
reported judicial decisions interpreting such law, as currently in effect, and we express no opinion as to the effect of any other law
of the State of Delaware or the laws of any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to
the filing of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to our firm under the caption &ldquo;Legal
Matters&rdquo; in the Prospectus. In giving such consent, we do not thereby admit that we are included in the category of persons whose
consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder. We assume
no obligation to update or supplement any of the opinion set forth herein to reflect any changes of law or fact that may occur following
the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Very Truly Yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>/s/ Sichenzia Ross Ference Carmel LLP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Sichenzia Ross Ference Carmel LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1185 AVENUE OF THE AMERICAS | 26TH FLOOR | NEW
YORK, NY | 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">T (212) 930-9700 | F (212) 930-9725 | WWW.SRFC.LAW</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea029163701ex23-1.htm
<DESCRIPTION>CONSENT OF BUSH & ASSOCIATES CPA LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ea029163701_ex23-1img1.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">To Whom it may concern:</P>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: justify">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report
dated April 1, 2026, relating to the financial statements of iSpecimen, Inc., which are contained in that Prospectus, relating to the
S-3 schedules, which are contained in the Registration statement.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">We also consent to the reference to us under the caption &ldquo;Experts&rdquo;
in the Prospectus.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Very truly yours,</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">/s/ Bush &amp; Associates CPA</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Bush &amp; Associates CPA LLC (PCAOB 6797)</P>

<P STYLE="margin: 0">Las Vegas, Nevada</P>

<P STYLE="margin: 0">June 4, 2026</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">9555 S Eastern Ave., Suite 280, Las Vegas, NV 89123 &#9744;
702.703.5979 &#9744;  www.bushandassociatescpas.com</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ea0291637ex-fee.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Template (c) 2024-2025 Novaworks, LLC -->
<!-- Field: Set; Name: AliasFileType; Value: Forms View; Template: Fee Exhibit\Fee Exhibit FE.xds -->
<!-- Field: Set; Name: Platform; Value: Novaworks Fee Exhibit Editor; Version: 1.4a -->
<!-- Field: Set; Name: Control; Value: VGVtcGxhdGU6IChkZWZhdWx0KQ0KQmFzZSBGb250OiBUaW1lcyBOZXcgUm9tYW4sIFRpbWVzLCBTZXJpZg0KQ2FwdGlvbiBTaXplOiAxMnB0DQpUYWJsZSBUaXRsZSBTaXplOiAxMXB0DQpUYWJsZSBIZWFkIFNpemU6IDhwdA0KVGFibGUgQm9keSBTaXplOiAxMHB0 -->
<!-- Field: Set; Name: MD5; Value: d0346468cf81b01aa1244e2a009542ed -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
  <title>Filing Fee Exhibit</title>
  <meta http-equiv="Content-Type" content="text/html"/>
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">

<div style="display: none">
  <ix:header>
    <ix:hidden>
      <ix:nonNumeric name="ffd:SubmissnTp" contextRef="c_report" id="fee_001">S-3</ix:nonNumeric>
      <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="c_report" id="fee_002">EX-FILING FEES</ix:nonNumeric>
      <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="c_report" id="fee_003">0001558569</ix:nonNumeric>
      <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="c_report" xs:nil="true" id="fee_004"></ix:nonNumeric>
      <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="c_report" id="fee_005">N/A</ix:nonNumeric>
      <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="c_report" id="fee_006">N/A</ix:nonNumeric>
      </ix:hidden>
    <ix:references>
      <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
      </ix:references>
    <ix:resources>
      <xbrli:context id="c_offering_1">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001558569</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-06-01</xbrli:startDate>
          <xbrli:endDate>2026-06-01</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_report">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001558569</xbrli:identifier>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-06-01</xbrli:startDate>
          <xbrli:endDate>2026-06-01</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:unit id="USD">
        <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="pure">
        <xbrli:measure>xbrli:pure</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="shares">
        <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unit>
      </ix:resources>
    </ix:header>
  </div>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right">Ex-Filing Fees</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">CALCULATION OF FILING FEE TABLES</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><ix:nonNumeric name="ffd:FormTp" contextRef="c_report" id="fee_007">S-3</ix:nonNumeric></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="c_report" id="fee_008">iSpecimen Inc.</ix:nonNumeric></p>

<p style="font: bold 11pt Times New Roman, Times, Serif; border-top: Gray 3pt double; padding-top: 6pt; text-align: center; margin-top: 0pt; margin-bottom: 4pt">Table 1: Newly Registered and Carry Forward Securities</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font-size: 2pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="width: 12%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 6.5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="border-bottom: Black 1pt solid">Line Item Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Class Title</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Notes</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Calculation<br/> Rule</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Amount Registered</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Proposed Maximum Offering<br/> Price Per Unit</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Maximum Aggregate Offering Price</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Rate</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Amount of Registration Fee</td></tr>
<tr style="font-size: 2pt; vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="22" style="padding-top: 2pt; font-style: italic; text-align: center; padding-bottom: 2pt">Newly Registered Securities</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_1" format="ixt:booleanfalse" id="fee_009">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_1" id="fee_010">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_1" id="fee_011">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(1)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_1" format="ixt:booleantrue" id="fee_012">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="shares" decimals="0" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_013">488,290</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_014">3.2150</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_015">1,569,852.35</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_016">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_017">216.80</ix:nonFraction></td></tr>
<tr style="font-size: 4pt; vertical-align: top; text-align: left">
  <td style="width: 11%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Offering Amounts:</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_018">1,569,852.35</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_019">216.80</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fees Previously Paid:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fee Offsets:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_020">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Net Fee Due:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 3pt double">$</td>
  <td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_021">216.80</ix:nonFraction></td></tr>
</table>

<p style="font: bold 8pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt">__________________________________________<br/>
Offering Note(s)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_1" id="fee_022">Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions. Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) of the Securities Act of 1933, as amended, based upon the average of the high and low prices for a share of the registrant&#8217;s common stock as reported on the Nasdaq Capital Market on May 29, 2026. Consists of (i) up to 85,202 shares of common stock and (ii) up to 403,088 shares of common stock issuable upon exercise of pre-funded warrants, all of which were issued in connection with a private placement transaction completed on May 11, 2026, pursuant to a securities purchase agreement, dated as of May 8, 2026, and which shares are offered for resale by the selling stockholders named in the prospectus.</ix:nonNumeric></td></tr>
  </table>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ea029163701_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029163701_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ] 1T# 2(  A$! Q$!_\0
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MM;[=X<^(>EZ*X.L^,_ 9P&VPR'?XK\-EFEL92#&WV?*1_NLKJ26/4]A^'O\
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M>#TP?\_[U.S[/[G_ )$\T?YH_P#@4?\ Y(L44F1QR.>G/7Z>M5_M /3'^?\
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M6S+]UB#_ *'6L^(-(\-Z1JNOZY>VNCZ5I%CJ.K:SJ-]<"SL;#3-'0RZOJDS
MD)%$I:20OP0-Q<YR_P"#_@+_ (.(/V#OB!X^\$^ =$\%_'R#7O'WB_PWX,TB
MZO?AKI*Z>FK>(=9.A:*-6F7Q07A1G&X9$C(ORH<@51_X.,/CSXC^$'[#>D>
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M(WQ8\,:3\"/^$JT7P_XTU5=2T[3]57QGH6@'6D.,AF1Y4R""%D< _,<^)_\
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MR4DJG(XRY*B<G]IDOBOE7]C36<76=91"SC9KVLG%J+2:3=[KFLGWNU9'NO\
MP6%_X+@ZWI.NZQ^S%^P[X\NM"UKPSK+VOQ>^.FA.TCZ;J6CLLI\$?#(^9)%(
M\4FX>,_%*YCMHV,$!$8+2?IE^Q/\<_C)X[_X(E7WQY\9?$GQ1XC^,:_ 3]H;
MQ/%\2=6O5_X20:KX;D\?/H&M)JI 13;G0X'CD494[<!0B$_P4>*?A9X]\"^#
M?ASXW\4^%M1\.>&/BQ::IK'PZU75;0:<?%>F:%K"Z'KNLZ)@G'A[_A(65O\
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MZPO]O1R%GD=6& H(P/45]R?\'.'P\^(OCNZ_8Y_X0#X?^/\ Q\-,/QB.K?\
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M>+5"#C!\*U(PM%J%_9SC%)J*BVK05E=V2T6Q_'W_ ,$V?V2O#7[<?[4WP_\
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L6$P/0?E5<@'J ?J :LT4KONP<4U9I-=FDU]S37X  !T 'TXHHHH'MMH?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ea029163701_ex5-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029163701_ex5-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !/ +T# 2(  A$! Q$!_\0
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M0/#Y\120R0GQ'+##+XH&[0(X[:R259Y5^PXO#]G^TS_P<[ZG\&OVDX+;XA>
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M,HQY(U:"E&<H17_+QM1C>'O.+4M+M+1N\XG$_6O>2U[I_P##;_H>A_#;X:^
M/A!X2TSX?_#?PYIGA'PCI5WK%YI/A[2AMTVR.N:S/KVKMI<>/DB?7]8>0JQP
MKO@*" *_,[XV_P#!-"^^+_\ P5/_ &6/^"BT7Q9@T&T_9U^'OBGP5=_"EO#'
M]H7GBM]?T+X@Z&-3@\0OKB#1O+3QNQ0):N2D7[U0Q96_53PKXBA\5>'M(\16
MT-Q:P:G9B\6UN1\ZJW R3D\$9' !Z?PU_.9_P4J_X*#_ /!0'X:?\%/OV7OV
M ?V,;[]G_1;O]HGX4ZQXIL]9^-_@;Q'KVGZ?XFT%/B!KDBOJOA[Q' 0I\.>!
MG;RF@ \P^9&@D*FO,X9H9[B\TS'^R<="G4EDV:_6Y5I^[]7C!_6VYN-1RE[)
M275Z:O=F6'WM%MOE=FD]WHM?6S>^G<^T?^"C?_!+^\_;/^+W[)W[3'PJ^+]I
M\ _VB?V2?'O_  D?AOX@CPG)XI_X2'PJS#5Y/!.NQCQ%X7+: URDH,:/)B#Q
M!X@!/[QZP_V\_P#@DRG[4'QJ^&7[9'P!^.?B?]E+]M_X/:''X7\/_&GPKI$7
MB/0?%?AIUN"_AOQUX)N)HX?$?AP'6=6CB1I$93*4D)CC$@P/A=>?\%KOAUK'
MC#QY^UC\0?V%O$WP>\(_"[XF^)[[2_@OX"^)6G>-I/$^@^#]9UGP:@F\3>(6
MMI- 778ML\2DW2P*VP(^QA^<7_!/3]LK_@O%_P %(/@'<_M#_"?XD?\ !/GP
M?X33XA>+/ 3:/XZ^#_Q0;Q$E[X/?1&D+MX?^(_DJKMJ;EMS?+LX"AP#]#@L!
MQ#1PWUK#\0Y"L!DL5AI3G-R<UG2FWA9<V!E[:%Z=3FHS3A"5Y1L[R>_^U*]F
MVEIM=+RT]59GVAH7_!&[XX_'S]H3X2_M!?\ !3S]L9?VN3\ ]8;Q3\(?@KX*
M^$VD_"'X&Z7XI>1&;7/$'AT^(?%K^(9B-'T60+/Y1+*V\@;@>Z^,W_!+7]I[
M1?VF/B/^U-^PK_P4&^(W[/\ XJ^+\B7GQ#^%/QA\+M\??@G?:JH,8O-!\/\
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M7U5]:?1- \/Z"A@T'P^-<S,(D>7)C0-'&L94?KH-HZ'ZYXY&,^W<#WK^0?\
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MT0_%SXOZA\+/ Z^&$^SVGQ+^(<GA/0'T)95'&G>+_$20O;*<G9%'<+O8-\N
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M2I5A2:<G92M)*22Q,WRZ25DG=Q;;U6_W6WVU2L?RP_#WXJ^%_P#@D)_P7?\
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9LEM=G$Z[5U=]MDG?7SW[>0M%%%>0<Y__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ea029163701_ex23-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029163701_ex23-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* ?H# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/>'-$T^$#=<:AJNISVUI '<K%!&TOFW-Q)%;6\<L\L<; ';T5^(MG_P<;_\
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MI/A3PI\0](\0^&_"WAK7;VP3^QD\3^+=6UNUU.XTJWFD2>\M=?O+'S[;3'G
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MO"?BOP)XLA\)>.=.T19W=M/TGQ!;2)J<UHI>-;S386C5?,D)_;;QQ_P=$?\
M!*VS_8^UCXZ^%_CM:ZK\4[SX>W%UH'[/AT?6(_BJOQ!O-*>*S\+:IHYLOLEE
M;V6M.L>H^('OCH/V""6\M-0N4DMUF_#7_@T _95^*7Q-_:#_ &N_^"CGCOP]
M?Z%X#\::5XM^'O@[4;B*6*R\3^-_B!XMA\6^-9-%FF2,ZEIWAJRB%A>7$:A(
MKS4K2,G?N50#XB_9D^$M_P#\'&G_  7R^/UY^U/XI\3ZC^SM\'Y_B/XC@\%:
M7K5S8):_"+X;>,[7P'\-OAKX>EB93H%KXAO-2M-=\4W^G+%>W5Q)K]PDWVR_
M2=/W7_X*C_\ !J!^S_\ %OP3\/\ Q1_P3/T'PY^S+\<O!?B'3UU.&]\3^)+;
MP=XG\.1AI4U-Y3-J-YI'C#0[Z*"\L=6T\PS7P8QW++)#%,/P=_8[^-2?\&\?
M_!?C]HGPW^UGHGB#P]\"/BC<_$;PC+XTL=%OM0B3X5_$GQG:^/OA5\4M'MH$
M:XU[0["33+31?$D>E)=7=C.=>A6![[1Y;1OZ _\ @JC_ ,'6?[-?P#\!^ ]$
M_P""<OBWP%^U=\</&6OV;ZE&=+\47?@?PEX6*,IAO[F"'29[_P 5ZQ>2V]II
MVBZ?--=6>V26_A0M%$X!B?\ !>CP)^T3\,/^#:W2?AQ^UCXJT+QU\?\ P+K/
M[/\ X6^(7C+P]=W5_IOB:^T7XI:19:7J_P!KOHX[NYOKC0XM,&I7,Z^;<ZBE
MS<L2TIKZ9_X-Q_ VN_$S_@WR^&WP[\+_ !!UGX3:_P".-/\ VDO"^F?$OPW%
M9R:_X&NM<^)OCK3_ /A)]%6_1[--5TE)WN[&>=2MO<QQW (>)6'S+_P7F^(_
M[0/QA_X-K-(^*G[4G@S0?AW\=/B'J_[/OB_QSX'\-Q:A;Z7X9FUSXH:1?:/I
MHM]4DEO[:\709M+FU&UN7,MI?37%L^&A(KY=_97\7_&[P+_P9N^./$O[/U[K
MFF>/K/1OBQ;7.K>&)KB#Q%I/@G4_VD;_ $SX@7VDW%FRW=M-%X0N]72ZNK4B
M>TTV2^ND>'R3/$ <A\&?^"=7_!N-_P $Z?&'Q9B_;\_;5^%'[8_Q<UWQ!<I:
MZ;XYU"XUIO"%JA>74DO-!\&S:I9:IXJU"_DDEOM8O[MIH2/(MX8F:1Z_'+]D
M7XM?LR?"'_@Y)_9\U;_@EMXJ\5Z/^RS\0?V@OAU\/[+3[IM6TW3M2\,?$>"S
M\-?$CPI;VFHS/?ZAX.-UJ6H3:$FK>9);RI;2P1PI9VJQ_7__  ;V^$?^#?:?
M]E_Q9\1?^"B?BSX*W7[5FG^-_$ESK^C?M&^+;[2-,TWP?;W"2^&K[P#HLU]I
MUEXEEU"TW3:U)'_;>HMJ<AMA;Q':K_)=C\<?V;/V@_\ @Y>_9#^('[('P[TO
MX<?LUQ?M.?LZ>%?A-::+X17P/H_BG0/"WB*PTFZ\;Z7X?6TLV@T_Q#KD.JM9
M74T7VB]MK6*YN2MQ)+%& ?KY_P 'DW[&?[-GPU^'7PK_ &MO!7PQTK0_VA/C
ME\<)M&^*'Q&MKF^.I>*],T#X=V&FZ5:WUM+<O8J+2RTC38(I(+>*39:J'9\C
M'[:_\$&O^">_[%O[/W[$'[+7[</P]^"FB^&?V@O''[+>GZE\0/B):ZAJTVIZ
M_'J5E/J'B!YH+J\FL('U$V2&1K>UB"*B(!M7GX'_ .#U/PSK^I_L'_LV^)=/
MTF]O-"\-?M$W-OK^IV\$DMKI,NN^"]0CT@7TJ*5MUOI-.O(X'D*H\D)C#;F4
M'[G_ .#?K_@HG^QO^U'^P7^SC^Q=\//BM;WW[0WPO_9IM_#WQ+^%]]HNMZ?K
M&AQ:4EQH>K7L-Y=V$6C:M9*]]#+%)INHW#O!(LCQHH+4 ?Q>_";]H/\ 8K_X
M*6?\%>/VA_VG?^"QGQ\O/"7[/WA74_$UQ\,/AS=3^(QIOB?3-!\6+X?^''PM
MM)M#$UUH/AC1/#GVCQ+XBBL/LO\ ;VK17*SN%U>]5_7_ /@M5HW_  03?X/^
M!OCG_P $F_B_H?PU_:<^&_CSPXC> ?AQ'XTTJP\6>')6N;K_ (2BS;4XHX-!
M\3>#-4LK&[MM3T^>"XOXKTI.&:TB<</^Q]X'_8S_ ."7G_!8/]IS]E[_ (+
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M_L?AY\&/"OBN?Q)XU\9>-?$D$$>D_P#"4^(1>WMOI&BVLA:>\.B:7;PL1=W
M_JU_X(%?\$^OV'OC)_P2<_9&^(/Q2_92^!?COQQKO@[4KC7/%GB;X?:'JVO:
MQ<IKVH1+<ZEJ-Y;RW%U,(XXXP9'*JB *JY;/]'7PM^"OP>^!N@'PQ\&_A?\
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MQAU2[\-_!'X Z>WA*U\1:+:3SQV;'Q9XHBM-3B,]Q%")?%4MP2\HQ)^\K?\
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MCWS7]KO_  <LRF']ACP*P.,_M ^ Q^=MJW^>E?PZ?;#TW_KP?P_GFO\ <_Z
M=%5/HZ9;)J__ !FO'"^['9-_F>-C:CCB&KV]V#WMNGYG7_;3Z]>F&[?B3QW)
M]<"OZ<?^#96X\[XQ?M2C.2OP\\%]QQGQ YZ?B.OT]Z_E?^V'^_GZ''X_YY]O
M7^H?_@V!G,WQF_:J!.2OPY\$Y.3_ -#"V"?KZU]Y],.@H_1K\59)6ME&5/\
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M:/P!^T%,/AWXOT5I]FG3:U/$[>$M=,;;HDO[#40L!N$"S2V<CVS-Y;D5_?\
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M&C23S>';[7K.XLO%'A>>Y0I<3>%_&.B7.F>*?#[7 Q]JCTK5[6"[VH+J*95
M'V!10!^(_P !/^#=3_@C[^SIXXT[XC>"/V0/#&N^+-%U*VU?0KOXF^)_&WQ0
MTW1=1LK@75E=V/AWQQXBUKP[]HLYUCEMI[K2[F:&2**2-UDC5A]&Z5_P2!_X
M)V>'/VGT_;*\(?LW^'_ _P"T>OB>7QC_ ,+%\#>(_&W@^5_$-U"T&H7LOAWP
M]XDT_P *RQZK'))_:UE)HC6&I22/->6TTK%Z_2NB@ K\V[3_ ()%?\$\K/\
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MI;HQB-GY1*'ZVOO^"0/_  3COOC[\+?VG%_9>\%:9\9O@I!X#M?A9XDT"_\
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M2GD>/<?JWU-Q=7ZP_:^TNH0Y;/S,5E\L36=55E33C&/+[/FUC?6_,M[[6/\
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MRT%[;0W4+$="8ITD0D=B5XI--TW3M,MDM]-L++3[=<D06-K!:0@M]XB*".-
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M<%:,5IU;?5M]6WJW^222****^,- HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Jun. 01, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001558569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">iSpecimen Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Jun. 01, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">488,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">3.2150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 1,569,852.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 216.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions. Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) of the Securities Act of 1933, as amended, based upon the average of the high and low prices for a share of the registrant&#8217;s common stock as reported on the Nasdaq Capital Market on May 29, 2026. Consists of (i) up to 85,202 shares of common stock and (ii) up to 403,088 shares of common stock issuable upon exercise of pre-funded warrants, all of which were issued in connection with a private placement transaction completed on May 11, 2026, pursuant to a securities purchase agreement, dated as of May 8, 2026, and which shares are offered for resale by the selling stockholders named in the prospectus.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Jun. 01, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 1,569,852.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">216.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 216.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0291637ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0291637ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0291637ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="ea0291637ex-fee.htm">ea0291637ex-fee.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0291637ex-fee.htm": {
   "dts": {
    "inline": {
     "local": [
      "ea0291637ex-fee.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/ffd/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 1
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 20,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0291637ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0291637ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0291637ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0291637ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0291637ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0291637ex-fee.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-26-065389-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-065389-xbrl.zip
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M0U\<7M%;WSX3K<FI>ZA__MV__N/F-PDXK^GM!?X_F[]]--^]N^G<=SL]GSO
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MP%\MX-Z!/VAH_AM02P$"% ,4    "  TJ\1<\TXF D<+  #6-0  $P
M        @ $     96$P,CDQ-C,W97@M9F5E+FAT;5!+!08      0 ! $$
(  !X"P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea0291637ex-fee_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001558569</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-01</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001558569</identifier>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">S-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0001558569</dei:EntityCentralIndexKey>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_004" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_005">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="c_report" id="fee_006">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_007">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_008">iSpecimen Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_009">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_010">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_011">Common Stock, $0.0001 par value per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_1" id="fee_012">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c_offering_1"
      decimals="0"
      id="fee_013"
      unitRef="shares">488290</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_014"
      unitRef="USD">3.2150</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="USD">1569852.35</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_016"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_017"
      unitRef="USD">216.80</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_018"
      unitRef="USD">1569852.35</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_019"
      unitRef="USD">216.80</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_020"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_021"
      unitRef="USD">216.80</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="fee_022">Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions. Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) of the Securities Act of 1933, as amended, based upon the average of the high and low prices for a share of the registrant&#x2019;s common stock as reported on the Nasdaq Capital Market on May 29, 2026. Consists of (i) up to 85,202 shares of common stock and (ii) up to 403,088 shares of common stock issuable upon exercise of pre-funded warrants, all of which were issued in connection with a private placement transaction completed on May 11, 2026, pursuant to a securities purchase agreement, dated as of May 8, 2026, and which shares are offered for resale by the selling stockholders named in the prospectus.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
